An Effectiveness -Implementation Trial of SPI[INVESTIGATOR_644917] 
(Short title: SPI[INVESTIGATOR_644918])  
Supplement  Trial : SPI[INVESTIGATOR_644919]: [REMOVED]  
 
Protocol Version Date : 8 April  2021 
 
  
NIH Behavioral and Social Research Clinical Trial Protocol Template    
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_863394] 
(Short title: SPI[INVESTIGATOR_644918])   
Supplement  Trial : SPI[INVESTIGATOR_644920] (NCT) Identified Number: [STUDY_ID_REMOVED]  
Principal Investigator:  [INVESTIGATOR_644921]-Kyung Song  
Funded by : [CONTACT_4289]/NINR, R01NR017018 /5R01AG057714.  
Version Number:  v.13 
8 April  2021  
 
 
Summary of Changes  from Previous Version:  
Affected Section(s)  Summary of Revisions Made  Rationale  
4.2 Scientific 
Rationale for Study 
Design  
5.1 Inclusion Criteria  
5.5 Recruitment  
[IP_ADDRESS] Conflict of 
Interest Policy  
 
 Inclusion of a new recruitment site.  
 Expanding recruitment locations to meet 
target sample size .  
 
 
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   ii Table of Contents  
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ ................................ .......  1 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ................................ ...... 2 
1.1 Synopsis  ................................ ................................ ................................ ................................ ..................  2 
1.2 Schema  ................................ ................................ ................................ ................................ ...................  4 
1.3 Schedule of Activities (SoA): Randomization occurs at the clinic level  ................................ ..................  6 
2 INTRODUCTION  ................................ ................................ ................................ ................................ .................  6 
2.1 Study Rationale  ................................ ................................ ................................ ................................ ...... 7 
2.2 Background  ................................ ................................ ................................ ................................ .............  9 
2.3 Risk/Benefit Assessment  ................................ ................................ ................................ ......................  14 
2.3.1 Known Potential Risks  ................................ ................................ ................................ .......  14 
2.3.2 Known Potential Benefits  ................................ ................................ ................................ . 14 
2.3.3 Assessment of Potential Risks and Benefits  ................................ ................................ ..... 14 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ................................ .........................  14 
4 STUDY DESIGN  ................................ ................................ ................................ ................................ .................  17 
4.1 Overall Design  ................................ ................................ ................................ ................................ ...... 17 
4.2 Scientific Rationale for Study Design  ................................ ................................ ................................ .... 18 
4.3 Justification for INTERVENTION ................................ ................................ ................................ ............  19 
4.4 End of Study Definition  ................................ ................................ ................................ .........................  19 
5 STUDY POPULATION  ................................ ................................ ................................ ................................ .......  20 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................................ ... 20 
5.2 Exclusion Criteria  ................................ ................................ ................................ ................................ .. 21 
5.3 Lifestyle Considerations  ................................ ................................ ................................ .......................  21 
5.4 Screen Failures  ................................ ................................ ................................ ................................ ..... 21 
5.5 Strategies for Recruitment and Retention  ................................ ................................ ...........................  21 
6 STUDY INTERVENTION(s)  ................................ ................................ ................................ ................................  23 
6.1 Study Intervention(s) Administration  ................................ ................................ ................................ ... 23 
6.1.1 Study Intervention Description  ................................ ................................ .........................  23 
6.1.2 Dosing and Administration  ................................ ................................ ...............................  24 
6.2 Preparation/Handling/Storage/Accountability  ................................ ................................ ....................  [ADDRESS_863395] Storage and Stability  ................................ ................................ ...........................  25 
6.2.4 Preparation  ................................ ................................ ................................ .......................  25 
6.3 Measures to Minimize Bias: Randomization and Blinding  ................................ ................................ ... 25 
6.4 Study Intervention Compliance  ................................ ................................ ................................ ............  26 
6.5 Concomitant Therapy  ................................ ................................ ................................ ...........................  27 
6.5.1 Rescue Medicine  ................................ ................................ ................................ ...............  27 
7 STUDY INTERVENTION DISCONTINUATION AND PA RTICIPANT DISCONTINUATION/WITHDRAWAL  .............  27 
7.1 Discontinuation of Study Intervention  ................................ ................................ ................................ . 27 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ ................................ .... [ADDRESS_863396] to Follow -Up ................................ ................................ ................................ ................................ . 27 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................ ................................ ................................ .......  28 
8.1 OUTCOME Assessments  ................................ ................................ ................................ .......................  28 
8.2 Safety and Other Assessments  ................................ ................................ ................................ .............  31 
8.3 Adverse Events and Serious Adverse Events  ................................ ................................ ........................  31 
8.3.1 Definition of Adverse Events (AE) ................................ ................................ .....................  31 
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   iii 8.3.2 Definition of Serious Adverse Events (SAE)  ................................ ................................ ...... [ADDRESS_863397] ................................ ................................ ................................ .. 32 
8.3.9 Reporting of Pregnancy  ................................ ................................ ................................ .... 33 
8.4 Unanticipated Problems  ................................ ................................ ..........  Error! Bookmark not defined.  
8.4.1 Definition of Unanticipated Problems (UP)  ................................ ................................ ...... 33 
8.4.2 Unanticipated Problem Reporting  ................................ ................................ ....................  33 
8.4.3 Reporting Unanticipated Problems to Participants  ................................ ..........................  33 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ .......................  33 
9.1 Statistical Hypotheses  ................................ ................................ ................................ ..........................  33 
9.2 Sample Size Determination  ................................ ................................ ................................ ..................  35 
9.3 Populations for Analyses  ................................ ................................ ................................ ......................  35 
9.4 Statistical Analyses  ................................ ................................ ................................ ...............................  35 
9.4.1 General Approach  ................................ ................................ ................................ .............  36 
9.4.2 Analysis of the Primary Endpoint(s)  ................................ ................................ ..................  36 
9.4.3 Analysis of the Secondary Endpoint(s)  ................................ ................................ .............  [ADDRESS_863398] Policy  ................................ ................................ ................................ .. 49 
10.2 Protocol Amendment History  ................................ ................................ ................................ ...............  49 
11 REFERENCES  ................................ ................................ ................................ ................................ ....................  53 
 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   1 STATEMENT OF COMPLIANCE  
 
The trial will be carried out in accordance with International Conference on Harmonisation Good Clinical Practice 
(ICH GCP) and the following :  
 
• [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR 
Part 50, 21 CFR Part 56, 21 CFR Part 312 , and/or 21 CFR Part 8 12)  
 
National Institutes of Health ( NIH)-funded investigators and clinical trial site staff who are responsible  for 
the conduct, management, or  oversight of NIH -funded clinical trials  have completed Human Subjects 
Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials have been 
appro ved by [CONTACT_4707] ( IRB) at: 
Emory (Study No.: IRB0094859; approved on 3/3/2017)  
University of New Mexico ( Study No: 17 -357 approved on 10 -27.17 ) 
University of Pi[INVESTIGATOR_9109] ( Study No.: PRO07070106; approved on 09/08/17)  
University of North Carolina at Chapel Hill ( Study #: 17 -1295; approved on 7/28/2017)  
 
RRI Carolina Dialysis approval (08/03/2017)  
FMC approval  4.1.18  
DCI approval & IRBAA  1.22.18  
 
Any amendment to the protocol require s review and approval by [CONTACT_52590].  In addition, a ll changes to the consent form will be IRB -approved . 
 
  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   2 1  PROTOCOL SUMMARY  
1.1 SYNOPSIS   
Title:  An Effectiveness -Implementation Trial of SPI[INVESTIGATOR_644923] : This multicenter, clinic -level cluster randomized trial will evaluate the effectiveness 
of SPI[INVESTIGATOR_61192], an advance care planning  (ACP)  intervention, delivered by [CONTACT_645135] -standing outpatient dialysis c linics 
compared to usual care. Simultaneously, we will evaluate the implementation of 
SPI[INVESTIGATOR_61192], including its sustainability.   
Objectives:  
 Primary Aim 1 . Examine the effectiveness of SPI[INVESTIGATOR_644924]-of-life decision making (defined as dyad 
congruence on goals of care, patient decisional conflict, and surrogate decision -
making confidence) at [ADDRESS_863399] -intervention  
 Aim 2 . Evaluate the process outcomes of SPI[INVESTIGATOR_644925]: acceptability, 
fidelity, intervention costs, and sustainability during the initial and delayed 
implementation of SPI[INVESTIGATOR_61192]  (Descriptive aim to generate data for translation)   
Aim 3 . Examine the effectiveness of SPI[INVESTIGATOR_644926]’ post -
bereav ement distress (anxiety, depression, and post -traumatic distress 
symptoms) at 3 months after the patient’s death  
Aim 4 (exploratory) : Examine the effectiveness of SPI[INVESTIGATOR_644927] -of-
life treatment intensity (healthcare utilization; percentages  of patients 
hospi[INVESTIGATOR_057], having ICU admission, and having intensive procedures and 
length of hospi[INVESTIGATOR_4408]) during the final month of life   
 In a supplement study , we will pi[INVESTIGATOR_644928] a model for determining whether patients with dementia 
superimposed on complex multimorbidity can fully participate in an advance care 
planning discussion.  
Supplement Aim 1 . Estimate  the effects of the SPI[INVESTIGATOR_61192] -dementia intervention on 1) 
the preparedness outcomes [ADDRESS_863400] intervention, 2) care decisions assessed 
at [ADDRESS_863401] intervention or the patient’s death.  
Supplement Aim 2. Estimate the effects of the SPI[INVESTIGATOR_61192] -dementia intervention on 
surrogates’ post -bereavement distress at 1 months after the patient’s deat h. 
Supplement Aim 3. Explore the relationships among patients’ cognitive status, 
decision -making capacity and their ability to express end -of-life wishes.  
 
 A new supplement study is a longitudinal cohort study  leveraging the parent 
stud y. The objective  is to assess the effect of the pandemic on the stability of end -
of-life care preferences and on our key outcomes (dyad congruence on goals of 
care, patient decisional conflict, and surrogate decision -making confi dence).  
Aim 1.  Compare the stability of patients’ goals -of-care preferences over time, from 
pre-outbreak to during -outbreak, by [CONTACT_19313] (SPI[INVESTIGATOR_644929]) and estimate 
effect by [CONTACT_545] (Blacks and Whites).  
Aim 2 . Assess the stability in the preparedness outcomes (dyad congruence, patient 
decisional conflict, and surrogate decision -making confidence) comparing 
pre-outbreak to during -outbreak by [CONTACT_19313], and estimate race effect.  
Aim 3.  Examine the associations of th e COVID -19 Related Stress questionnaire, sex, 
race/ethnicity, and other sociodemographic characteristics (e.g., education 
level, income) to change in the outcomes  and the stability of patients’ 
goals -of-care preferences after the COVID -19 outbreak.  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   3  
Endpo ints: Primary Endpoint s (Aim 1) :  
Dyad congruence on goals of care, patient decisional conflict, and surrogate 
decision -making confidence at [ADDRESS_863402] -intervention  
Secondary Endpoints  (Aim 3) :  
Surrogate HADS and PTSS scores at 3 months after the patient’s death;  
Exploratory  (Aim 4) : 
EOL treatment intensity  
 
Supplement Aim:  
Dyad congruence on goals of care, patient decisional conflict, and surrogate 
decision -making confidence at [ADDRESS_863403] -intervention   
Study Population:  400 patient s and 400 surrogate s of the patients participate as pairs (400 patient -
surrogate dyads);  adults (>=18 y) ; both genders ; all race and ethnicity ; ESRD/chronic 
dialysis population  
 
For the supplement aims:  
[ADDRESS_863404] + cognitive impairment, including early stages of dementia, 
who are not eligible for the parent study due to cognitive impairment, and 30 
surrogates of the patients as pairs  
 
Supplement cohort study:  
~[ADDRESS_863405] -intervention 
assessment prior to the pandemic lockdown.   
Phase:  Phase III effectiveness trial  
 
For the supplement aims, NIH Stage 1 biobehavioral intervention research   
Description of 
Sites /Facilities  Enrolling 
Participants : Participants recruited from outpatient dialysis centers located in GA (Emory), NC 
(UNC -CH),  VA (UVA)  and PA (U of Pi[INVESTIGATOR_32887]) .; dialysis centers owned and managed by 
[CONTACT_606293], Fresenius Medical Care ( FMC ), Renal Research Institute ( RRI), 
and Dialysis Clinic Inc ( DCI).  
A total of 29 free-standing dialysis centers.  
 
For the supplement aims, only Emory dialysis centers will serve as study site.  
 
Supplement cohort study: no new participant recruitment from the clinic. Current 
study participants who are eligible for the cohort study will be contact[CONTACT_65312].   
Description of Study  
Intervention : SPI[INVESTIGATOR_61192]  (Sharing Patient’s Illness Representation to Increase Trust), a patient and 
family -centered ACP intervention based on the Representational Approach to 
Patient Education, is to establish a testable model of how end -of-life care 
discussions could occur between  a dialysis patient and his/her chosen surrogate 
(usually a spouse or adult child). The discussions, which are facilitated by a trained 
care provider, are framed around addressing each individual’s representations of 
(beliefs about) the illness and views o f life -sustaining measures at the end of life. 
SPI[INVESTIGATOR_644930] a six -step learning objective over two -sessions, which together take 
about 60 minutes.   
Study Duration:  60 months  
 
For supplement aims, up to 2 years.  
 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   4 Supplement cohort study: 2 years   
Participa nt Duration:  For patients , baseline and 2 -week follow up (active participation) , and then an 
observational period for 9 months  (or until death).  We will request extens ion of 12 
additional months at completion of 9  month  time point.  
For surrogates , baseline and 2 -week follow -up (active participation), and then a [ADDRESS_863406] -death follow -up survey at 3 months after the patient 
death (if t he patient  death occurs during the  observational period).  
 
For supplement aims,  
Patients : a brief survey at baseline and a follow -up at 2 -3 days after the 
intervention, and then an observational period for 12 months.  
Surrogates : a brief survey at baseline and a follow -up at [ADDRESS_863407] -death follow -up survey at 1 month after the patient’s 
death (if the patient death occurs during the observational period).  
 
Supplement cohort study: ~ 6 months once enrolled.  
1.2 SCHEMA  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   5  
 
  

SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   6 1.3 SCHEDULE OF ACTIVITIES (SOA) : Randomization occurs at the clinic level  
Days offset  Procedure  Note  
Patients and 
surrogates  Patient referralsa Screened and willing patients  
Patient screened (by [CONTACT_3647]) b Linked to eligibility checklist  
Day -[ADDRESS_863408] review : clinical characteristicsb To be linked to “pt  consent”  
 Usual care review 1b To be linked to “pt consent” & separate  
Every 6 months  
Day 0  Surrogate verbal consentb  
 Surrogate verbal  consent receivedb  
 Scheduling baseline (T1) appointment  If control, schedule both T1 & T2  
 Reminder call for T1   
Day 14 (+/ - 7) Baseline (T1) -patient completion  Link to the measures  
 Baseline (T1) -surrogate completion  Link to the measures  
 Payment (T1) mailed to patient  With thank -you note  
 Payment (T1) mailed to surrogate  With thank -you note  
 Scheduling SPI[INVESTIGATOR_644931]  I & II and 2-wk F/Ub Need to coordinate with the care provider  
for SPI[INVESTIGATOR_644932] T2  Central  
 2-week follow -up (T2) -patient completion  2 weeks fr om SPI[INVESTIGATOR_61192]; including  
acceptability survey  and SPI[INVESTIGATOR_644933]  
 2-week follow -up (T2) -surrogate completion  2 weeks from SPI[INVESTIGATOR_61192]; including 
acceptability survey  and SPI[INVESTIGATOR_644934] (T2) mailed to patient  With thank -you note  
 Payment (T2) mailed to surrogate  With thank -you note  
 Monthly check -in call [ADDRESS_863409]  Upon patient death  
 Contact[CONTACT_645136] & scheduling a [ADDRESS_863410] -death F/U   
 Postcard reminder 2 weeks before the F/U  
 Reminder call for 3 -month F/U   
 F/U [ADDRESS_863411] death   
 Payment (F/U 3M) mailed to surrogate  With thank -you note  
 Clinic -level contextual datab At the end of each implementation  
Care providers  Informed consentb At the end of each implementation  
 Acceptability assessmentb Brief survey and interview  
 SPI[INVESTIGATOR_644935] -sustainabilityb  
a Performed locally by [CONTACT_645137];  b Procedures performed locally by [CONTACT_2710]  
 
2  INTRODUCTION  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   7  
2.1 STUDY R ATIONALE   
 
End-stage renal disease (ESRD) currently affects nearly 662,000 people in the U.S.1 While dialysis is the treatment 
of choice for over  90% of patients with ESRD and is universally covered by [CONTACT_645138], the likelihood that dialysis can restore health or prolong life is limited; only 50% of dialysis patients are 
alive [ADDRESS_863412] to face difficult end -of-life decisions. Although advance care planning (ACP), in which patients and 
surrogate decision -makers discuss future health states and treatment options, is a central tenet of dialysis care,2-[ADDRESS_863413] majority of dialysis patients (>90%) report never engaging in ACP discussions with their care providers.6,[ADDRESS_863414] been well 
documented: prolonged use of futile treatment at the end of life, which misuses the healthcare system, high 
levels of surrogate distress during decision making, which emanates from not having a clear understanding of the  
patient’s wishes, and surrogates experiencing later sequelae of psychosocial morbidities, such as depression and 
family discord.8-14  
 
SPI[INVESTIGATOR_61192]  (Sharing Patient’s Illness Representation to Increase Trust), a patient and family -centered ACP intervention 
based on the Representational Approach to Patient Education,15,16 was designed by [CONTACT_645139] a 
testable model of how end -of-life care discussions could occur between a dialysis patient and his/her chosen 
surrogate (usually a spouse or adult child). The discussions, which are facilitated by a trained care prov ider, are 
framed around addressing each individual’s representations of (beliefs about) the illness and views of life -
sustaining measures at the end of life. SPI[INVESTIGATOR_644930] a six -step learning objective over two -sessions, which 
together take about 60 minut es. The care provider, who is value -neutral, guides the patient in examining his/her 
values related to end -of-life care, helps the surrogate understand the patient’s illness progression, and prepares 
the surrogate for his/her role as a surrogate in a highl y emotionally charged medical setting. Over the last decade, 
we have iteratively tested SPI[INVESTIGATOR_644936], patient -surrogate acceptability, and efficacy.17-20 In these 
explanatory trials carried out in dialysis clinics, SPI[INVESTIGATOR_644937]. Patients and 
surrogates in SPI[INVESTIGATOR_644938] -of-life decision making, including 
the extent to which: a) the pati ent and surrogate agreed on end -of-life care goals, b) the patient had reduced 
conflict about the benefits and burdens of life -sustaining treatments, and c) the surrogate had increased 
confidence about the role of surrogate. Key to establishing the utility  of this approach for broader generalizability, 
surrogates who received SPI[INVESTIGATOR_644939] -bereavement psychological outcomes after 
the patient’s death compared to those who did not. The logical, critical next step is to ask: Will SPI[INVESTIGATOR_644940] -world clinical settings with less control? To address this very issue, we will conduct a 
real-world effectiveness -implementation study, an essential step prior to widespread implementation of SPI[INVESTIGATOR_61192].   
 
For Supplement Aims:  
Cognitive impairment, including dementia, is common among individuals with ESRD but is a poorly recognized 
problem. The prevalence ranges from 16 -38% and up to 70% depending on the sample,5-8 but only less than 4% 
are formally diagnose d.7,[ADDRESS_863415] is vascular 
dementia  followed by [CONTACT_7351]’s disease .[ADDRESS_863416], the risk for poor outcomes, including disability, hospi[INVESTIGATOR_9017], sharply 
increases.11,12  Similarly, initiating dialysis in older adults with multiple comorbidities, including dementia, does not 
offer survi val benefit; a study of 3,700 nursing home residents found that half of the residents died within 6 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   8 months and more than 70% died by [ADDRESS_863417] majority of 
dialysis patients (>90%) across all age groups and comorbid conditions report never engagin g in advance care 
planning (ACP) discussions with their care providers.14,[ADDRESS_863418].  
 
In an on -going study (“SPI[INVESTIGATOR_644941],” R01AG057714) w hich is now running in parallel to the parent SPI[INVESTIGATOR_644942], we carefully adapted SPI[INVESTIGATOR_644943] . As 
part of the NIH Stage I behavioral intervention development trial,[ADDRESS_863419] ed the feasibility of the adapted 
SPI[INVESTIGATOR_644944] 23 dyads (74% white; mean age = 74 years) recruited from the Emory Brain Health 
Center. The goal of SPI[INVESTIGATOR_644945] -of-life decision making for 
patients with a serious or life -threatening illness and their surrogates. SPI[INVESTIGATOR_644946].17,18 We demonstrated that, by [CONTACT_645140][INVESTIGATOR_644947], persons with 
dementia (PWD) were able to engage in an ACP discussion meaningfully and exchange authentic dialogue with 
their surrogates about experiences surrounding illness and values. While the sample was small, our team was able 
to conclude that meaningful ACP conversations were possible even for individuals with moderate dementia and 
that decision -making capacity might be th e more important mental faculty than global cognitive functioning in 
ACP discussion. It is important to note that in most studies of ACP, including our own previous SPI[INVESTIGATOR_644948]1-[ADDRESS_863420] study,19 PWD (regardless of their cognitive impairment level) are rout inely 
excluded  from clinical trials, largely because investigators assume that PWD do not have the cognitive capability 
to appreciate the complexity of ACP.  
 
As a next step we are now conducting a full -scale RCT of the adapted SPI[INVESTIGATOR_644949] a nd surrogates 
to examine preliminary efficacy on immediate outcomes, including preparedness for end -of-life decision making. 
In the SPI[INVESTIGATOR_61192] -dementia study, we are targeting people with early stages of Alzheimer’s disease and related 
dementia. Therefore, in contrast to the patients in the ESRD study, PWD in the dementia study have a longer life 
expectancy (~10 years) and, for the most part, do not have complex multimorbidity. For patients with ESRD who 
have cognitive impairment, including dementia, the urgenc y for ACP is time sensitive because care decisions (e.g., 
discontinuation of dialysis, hospi[INVESTIGATOR_24194]) and surrogates’ bereavement are rather imminent.  
 
In this supplement study, we will pi[INVESTIGATOR_644950] (SPI[INVESTIGATOR_61192] -dementia) for patients with 
ESRD plus dementia as a model for determining whether patients with dementia superimposed on complex 
multimorbidity can fully participate in AC P discussion. The pi[INVESTIGATOR_644951] [ADDRESS_863421] plus dementia and their surrogates from Emory dialysis clinics that are currently participating in the 
parent study . 
 
Supplement cohort study:  
For patients with complex multimorbidity (e.g., ESRD), COVID -[ADDRESS_863422] serious chronic illness and prefer to forgo 
prolonged life support measures.7 The COVID pandemic has brought fear and uncertainty to all aspects of life and 
to medical care in particular. Research has shown that after experiencing a natural disas ter, people exhibit more 
risk averse behaviors, and that belief systems can change, i.e., people “update” their perception of background 
risk and perceive the world to be a much riskier place.8,[ADDRESS_863423] decade studying how to help individuals with a range of illnesses (and their caregivers 
/surrogates) clarify their end -of-life care preferences and prepare for end -of-life decision making to minimize 
unnecessary or unwanted end -of-life treatments in the face of life -limiting illnesses. We, through this body of 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.[ADDRESS_863424] so that we can gather evidence to revise/update our conceptual model to integrate best 
practices for ACP in the settings o f disasters.  
 
2.[ADDRESS_863425] their wishes.    Despi[INVESTIGATOR_644952], adjusted all -cause mortality rates are 6 -8 times greater for dialysis patients than for 
individu als in the general age -matched Medicare population.1 Only 50% of dialysis patients are alive [ADDRESS_863426].1  End-of-life treatment intensity in this population is also substantially greater than that 
report ed for other Medicare beneficiaries with life -limiting illnesses.21 For instan ce, in a study of older Medicare 
beneficiaries (≥ 65 years; N 100,000) those on dialysis experienced significantly higher rates of hospi[INVESTIGATOR_059] 
(76% vs 61% in cancer), ICU admission (48.9% vs 29% in cancer), and use of intensive procedures (29% vs 9% in  
cancer) during the final month of life.[ADDRESS_863427],23 withdrawal from dialysis and aggressive 
treatment is very rarely (< 6%) discussed by [CONTACT_645141] r 
alternatives such as hospi[INVESTIGATOR_644953].23-26 In a study of over 530 chronic dialysis patients, only 19% 
indicated that they would want to continue dialysis if severely cognitively or functionally impaired, and 65% stated 
that they prefer to die at home or in hospi[INVESTIGATOR_644954] a hospi[INVESTIGATOR_307].27 Patients’ preferences for end of life care 
are significantly influenced by [CONTACT_13935]’ illness representations (e.g., perceived illness severity).[ADDRESS_863428] discovered that because so many dialysis patients 
are unaware that they are likely to die from an acute illness or complication (e.g., stroke, in fection) rather than die 
from ESRD per se, they endorse the notion that with dialysis they can live as long as those without ESRD.18,29 
Similarly, surrogates are equally unaware of patients’ likely illness progression and comorbidities; surrogates 
report that prior to the time of end -of-life decision making they have not been told that the patient’s i llness 
cannot be cured.9 Studies indicate that spouses' judgments about dialysis patients’ preference s for continuation 
of dialysis were only modesty correlated with patients’ preferences ( r = .33),30,[ADDRESS_863429] 
little understanding of the patient’s preferences and yet report confidence in understanding the patient’s wishes 
and their role as a  surrogate.[ADDRESS_863430] on patients and surrogates. 
There are predictable psychologi cal and emotional consequences of lack of preparedness for end -of-life decision 
making. These include: high levels of conflict brought on by [CONTACT_645142] (e.g., whether 
to withhold or withdraw mechanical ventilation, prolonging us e of life sustaining measures that are deemed 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   10 futile); regrets over missed opportunities to benefit from palliative care or hospi[INVESTIGATOR_6125]; excessive distress for family 
members during decision making due to interfamily conflict, time pressure to make important d ecisions, lack of 
knowledge about options; and well documented psychosocial sequelae for family members (e.g., depression, 
anxiety, post -traumatic stress disorder) and complicated bereavement after the patient’s death.8,13,35-43 Numerous 
studies, including ours, indicate that families experience greater difficulty in decision making when they are 
uncertain about the patient’s wishes , when they feel unprepared for their role  because they have never discussed 
it, and when they are called on to make decisions in a short period of time.29,37,43-48 Evidence shows that this 
distress contributes to a high prevalence of psychiatric illness among family decision makers: in one study nearly 
40% of bereaved families who experienced a loved one’s death in the ICU [ADDRESS_863431] 
one psychiatric illness meeting DSM -IV criteria, such as anxiety disorder or major depression.42 Even at 6 -12 
months afte r the patient’s death, family members may experience intrusive thoughts of regret, guilt or search for 
evidence that they made the right decision.8,43,45,49,[ADDRESS_863432] the hypothesis that surroga tes’ post -
bereavement psychosocial distress will be reduced by [CONTACT_645143][INVESTIGATOR_61192], a patient and family -centered ACP, in a real -world 
setting.  
 
Usual care does not prepare patients and surrogates for end -of-life decision making. Usual  ACP in free -standing 
dialysis fa cilities is based on the Centers for Medicare & Medicaid (CMS) requirements51 that written informati on 
on advance directives (ADs) is provided on a patient’s first day of dialysis, and a member of the dialysis team (e.g., 
social worker) reviews the written information with patients and encourages them to complete an AD. If 
completed, the AD is documented on  the Plan of Care forms. If a patient expresses a desire not to be resuscitated 
in the dialysis unit, a do -not resuscitate (DNR) order is written by a nephrologist and placed in the clinic record. If 
there is no DNR order in the record, a full code is pres umed. CMS has recently issued two new billing codes (CPT 
[ZIP_CODE] and [ZIP_CODE]) effective in [ADDRESS_863433] 30 minutes and each additional 30 minutes 
of face -to-face services between a physician or other qualified healthcare profession al and a patient, family 
member and/or surrogate in discussing ADs, with or without completing relevant legal forms.52 Although this is 
encouraging, CMS provides neither ACP tools nor guidance to ensure consistency and quality in ACP services. CMS 
recommends that ACP d iscussions be conducted during annual wellness visits at a doctor’s office to which these 
codes can be added; ACP discussions occurring outside of these visits are subject to patient co -pay or deductibles, 
which limits utility of the policy in other care s ettings. Further, ACP in these codes is narrowly defined as 
“including the explanation and discussion of ADs” and thus it may reinforce a common pi[INVESTIGATOR_644955], i.e., a sole 
focus on AD completion.[ADDRESS_863434] and their surrogates. SPI[INVESTIGATOR_644946].15,16 This approach melds two theories: Leventhal’s common sense model54 and the 
conceptual change model.[ADDRESS_863435] representations of their 
illness or health problems. Because representations are based on an individual’s everyday exper iences, traditional 
or cultural information, or media, they may not be medically accurate. However, it is critical to understand the 
representations because they serve as the cognitive framework that affects whether or not individuals accept or 
reject new information,[ADDRESS_863436] and 
comment on current ideas and their consequences, when the individual is dissatisfied with current ideas or 
recognizes thei r limitations, and when alternative information is seen as beneficial.15,16,55,58 Learning/change can 
occur through integrating new information into existing representations to fill in gaps in understanding, through 
clarifying existing representations to reduce confusion, or through exchanging ex isting representations with new 
information.58,59 The Representational Approach to Patient Education requires a care provider to elicit the 
patient’s pre -existing illness representations before providing new information.15,[ADDRESS_863437] an opportunity to recognize gaps or confusions in the patient’s representations, and the 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.[ADDRESS_863438] on the new information.  
 SPI[INVESTIGATOR_644956] a two -session, 60 -minute, structured psychoeducational intervention, targeting both patient and 
surrogate . Using a provider manual, the care provider follows six steps: 1) assessing illness presentation, 2) 
identifying gaps and concerns, 3) creating conditions for conceptual change, 4) introducing replacement 
information, 5) summarizing, and 6) setting goals and planning (See Appendix ).[ADDRESS_863439] establishes an 
understanding of the cognitive, emotional and spi[INVESTIGATOR_644957]’s representation of his/her illness. 
This understanding enables the care provider to provide individualized medical information and to assist the 
patient in examining his/her own values related to life -sustaining treatment at the end of life. In this way, th e 
patient can more readily express his/her treatment preferences to the surrogate. SPI[INVESTIGATOR_644958]’s illness experiences and values and to be prepared for the responsibility and 
emotional turmoil that can arise d uring decision making at the end of life. Each element of SPI[INVESTIGATOR_644959]. During the process, the patient discovers his/ her own representations about illness and dialysis 
and examines thresholds and/or conditions for (dis)continuing life support measures. The surrogate gains an 
understanding of the patient’s illness experience and begins to see his/her limited life expectan cy. The surrogate 
also validates similarities or differences with the patient in regard to life support measures and examines his/her 
own ability to follow the patient’s wishes. This process is critical to preparation for end -of-life decision making.20,[ADDRESS_863440] providers in addressing the unique challenges and complexities in ACP with dialysis 
patients and surrogates. This evidence -based guide promotes quality, consistency, and fidelity in  ACP delivery60 in 
this pragmatic trial of SPI[INVESTIGATOR_61192].   
 
Preliminary data to support feasibility of the proposed cluster randomized trial in dialysis clinics.  
Three RCTs testing SPI[INVESTIGATOR_61192]18-20 were conducted in free -standing outpatient dialysis settings and established the 
feasibility, patient and surrogate acceptability, preliminary effects (R21NR009662), and efficacy of SPI[INVESTIGATOR_644960]. Dialysis facilities varied in type, including profit and non -
profit ownership, urban and rural, and academic affiliation and community. The PI ([CONTACT_461042]) has the intimate 
knowledge of implementing SPI[INVESTIGATOR_644961] x health care systems. Recruitment rates have consistently 
been over 80% with a very low dropout rate (<4%). Throughout these trials, we have tested strategies and 
procedures related to recruitment, retention, data collection, and SPI[INVESTIGATOR_644962], fidelity , and measurement.  
 
In a full -scale multicenter RCT (R01NR011464), we formally tested the efficacy  of SPI[INVESTIGATOR_644963] -of-life decision -making: Measured at 2, 6, and [ADDRESS_863441] -bereavement distress for surrogates (at 2 wks., 3 and 6 months).  For the RCT, 210 
dyads of seriously ill dialysis patients and their surrogates from 20 free -standing dialysis f acilities (mean age 62, 
57% women, 67% African Americans, 96% on hemodialysis) were randomized to SPI[INVESTIGATOR_644964].   Intention -
to-treat analysis showed that, adjusting for time and baseline values, dyad congruence on goals of care ( OR=1.89 
[95% CI, 1.1  to 3.3]; p=.029) and surrogate decision -making confidence ( β=0.13 [ CI, 0.01 to 0.24]; p=.027) were 
significantly better in SPI[INVESTIGATOR_61192]. Patient decisional conflict was significantly lower in SPI[INVESTIGATOR_644965] 12 months ( β=-0.19 [ CI, 
-0.33 to -0.04]; p=.011). We also c reated a composite outcome combining dyad congruence and surrogate 
decision -making confidence because surrogates can feel highly confident even if they misunderstand patients’ 
wishes.18,34 Thus, to differentiate surrogates who understand the patient’s wishes and feel confident in their role 
from those who do not (i.e., understand the wishes but lack confidence, misunderstand the wishes but feel 
confident, or neither understand nor feel confident), dyads were grouped as congruent in both scenarios and 
surrogate decision -making confidence ≥ 3 (“confident” to “very confident”), or not.18 SPI[INVESTIGATOR_61192]’s effect on the 
composite outcome was also significant (OR=1.82 [95% CI, 1.0 to 3.2]; p=.041).   
 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   12 Mortality rates between the groups were 
similar. Among 45 bereaved surrogates, adjusting 
for time and baseline values, those in the SPI[INVESTIGATOR_644966] ( β=-1.13 [ CI, -2.23 to -0.03]; 
p=.044), depression ( β=-2.54 [ CI, -4.34 to -0.74]; 
p=.006), and post -traumatic distress ( β=-5.75 [ CI, 
-10.9 to -0.64]; p=.027) than did controls.  
 
Our qualitative thematic analysis of post -
bereavement interviews with surrogates ( Box 1 ) 
helps e xplain how SPI[INVESTIGATOR_644967]’ 
post -bereavement distress.61 Our data revealed 
that s urrogates reported gaining insight about 
the life-limiting nature of the patient’s illness and that death  might be near; notably, no prognostic information 
was provided during the SPI[INVESTIGATOR_644968]. An important outcome 
was that the steps of SPI[INVESTIGATOR_644969].61   
 
For Supplement Aims:  
Adaptation of SPI[INVESTIGATOR_644970]: In contrast to 
people with ESRD, participants in the ongoing parallel trial (“SPI[INVESTIGATOR_644971],” R01AG057714) do not ha ve complex multimorbidity 
and are expected to live for ~[ADDRESS_863442] completed the iterative process of adaptation for persons with mild to moderate dementia 
and their surrogates and recently pi[INVESTIGATOR_644972] a sample of 23 PWD (a Montreal Cognitive 
Assessment [MoCA] score, M=17.7, SD=4.0, range, 13 -25; 74% non -Hispanic white; 50% male; mean age=74 
years) and their surrogates (65% female, 74% spouse). The PWDs also were assessed for their decision -makin g 
capacity using a screening test, the University of [LOCATION_004] San Diego Brief Assessment of Capacity to Consent 
(UBACC),38 at enrollment (M=13.2, SD=2.1, range 9 -16 out of 18). As part of the analysis, using a “quantitizing” 
technique of qualitative data analysis,39 we reviewed SPI[INVESTIGATOR_644973] n transcripts focusing on the values of 
treatment outcomes and the goals of care discussions, and rated the level of PWD’s articulation of end -of-life care 
preferences on a 3 -point scale (from 3=expressed wishes very coherently to 1=unable to express wishe s 
coherently).  
 
Preliminary findings: Of the 23 PWD, 14 PWD (60.9%) had moderate dementia (MoCA=13 -17). Of note, all 
23 PWD were able to articulate their values and end -of-life wishes somewhat or very coherently; 20 of them 
expressed their wis hes very cohe rently (rating=3 ). While MoCA (global cognitive functioning) scores did not differ 
by [CONTACT_645144], the UBACC (decision -making capacity) scores did, Kruskal -Wallis H = 5.57, df 
= 1, p = 0.02, with a mean rank score of 3.50 for a rati ng of 2 (somewhat coherent, n = 3) and 13.28 for a rating of 
3 (very coherent, n = 20).  
 
Our finding that meaningful ACP conversations were possible even for those with moderate dementia and limited 
decision -making capacity is an important finding because Hirschman et al40 found that as PWD’s cognitive 
impairment becomes advanced, family members use the best interest standard (what a reasonable person would 
do) more often than substituted judgement (what my loved one would have wanted). The primary reason for 
using the best  interest standard was that there had been no previous discussion about the PWD’s preferences.41 
Our data also show that decision -making capacity may be the more important mental faculty than global cognitive 
functioning in ACP discussion, particularly for eliciting end -of-life wishes.  However, the relationships among 
cognitive functioning, decision -making capacity, and ability to express wishes need future evaluation.  As part of 
the supplement, we propose to replicate the examination of one’s ability to express wishes about end -of-life care 
in a sample of patients with E SRD plus dementia to assess 1) if these patients have more severe cognitive Box 1. Perceived i mpact  of SPI[INVESTIGATOR_61192]: Themes  
SPI[INVESTIGATOR_61192]…  
a) was an eye -opening experience, acquiring 
knowledge and understanding of the patient’s 
illness, prognosis, and end -of-life care  
b) helped strengthen relationships between 
patients and surrogates  
c) helped surrogates feel prepared during the 
time leading up to end -of-life decision -making  
d) helped surrogates have peace of mind during 
and after actual end -of-life decision -making  

SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   13 impairment and how that impacts the ACP conversations, and 2) if complex multimorbidity, i.e., ESRD, impacts the 
ACP conversation across a range of dementia severity. The supplemen t also gives us the opportunity to evaluate 
the adapted SPI[INVESTIGATOR_644974] a largely African American sample who are disproportionately represented in conditions 
with multimorbidity and dementia.  
 
The adapted SPI[INVESTIGATOR_644947] (SPI[INVESTIGATOR_61192] -dementia) sessions lasted  100 minutes on average (range, 51 -122). The 
main reasons for the longer duration compared to earlier SPI[INVESTIGATOR_644948] (on average 82 minutes) were that the 
interventionist was required to: a) speak slowly, b) repeat questions for the PWD, and 3) ask clarify ing questions 
whenever the PWD’s response was vague. As is typi[INVESTIGATOR_644975], and the interventionist was prohibited from rushing, 
interrupting, or finishin g the sentence for the PWD. Although the intervention could have been broken down to 
two sessions, as in previous SPI[INVESTIGATOR_644976], we determined that a single session approach 
would be more appropriate due to PWD’s limited or absent s hort -term memory.  
 
Supplement Cohort Study:  
End-of-life preferences of patients with serious illnesses are generally stable.  A recent systematic review10 of 
evidence on the stability of end -of-life preferences over time found that more than 70% of patients’ preferences 
for end -of-life care were stable over time, and preference stability was generally greater among inpatients and 
seriously ill outpatients than among older adults without serious illnesses (p<.002;  N=55 studies; 24 studies for 
metanalysis). Further, patients who completed advance directives had more stable preferences than those who 
did not, suggesting that efforts to engage patients in actively thinking about these decisions can augment stability 
of preferences for treatment over time. These findings support that previously stated preferences for end -of-life 
care may be sufficiently stable to guide current care.  
Disasters, psychosocial impact, and decision making behaviors:  According to the National  Oceanic and 
Atmospheric Administration,[ADDRESS_863443] $[ADDRESS_863444] devastating disasters, has ki lled 100,000 Americans in less than 4 months (as of 
May 2020)[ADDRESS_863445] and disagreements with 
family members, and disengagement from seeking social support. Shortly after the 9/[ADDRESS_863446]  in the stock market (more risk averse in terms of investing behaviors) than 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.[ADDRESS_863447] of the COVIDE -19 pandemic on patients’ end -of-life preferences, to 
address whether the stability of preferences is disrupted by [CONTACT_47098], and to identify patient chara cteristics, 
including race/ethnicity, associated with pre -/post -pandemic changes.  
 
2.3 RISK/BENEFIT ASSESSMENT    
 
2.3.1  KNOWN  POTENTIAL RISKS  
 
As the SPI[INVESTIGATOR_644977], th is Phase III  pragmatic trial involves very 
minimal or low risk. Patient and surrogate participants may experience an emotional reaction (e.g., anxiety) or 
fatigue during the intervention or data collection. In our previous studies,17-[ADDRESS_863448] demonstrated the potential benefits of SPI[INVESTIGATOR_61192].   
 
3 OBJECTIVES AND ENDPOINTS  
 
The objective of this multicenter, clinic -level cluster randomized trial is to evaluate the effectiveness of SPI[INVESTIGATOR_644978] -standing outpatient dialysis clinics compared  to 
usual care plus delayed SPI[INVESTIGATOR_644925]. Simultaneously, we will evaluate the implementation of SPI[INVESTIGATOR_61192] , 
including sustainability. We will use a Type I effectiveness -implementation hybrid approach62,63 that combines 
testing intervention effectiveness and gathering information about implementation of an efficacious intervention 
in a real world setting. The short -term goal is to generate sufficient evidence to accelerate the integration of 
SPI[INVESTIGATOR_644979]. We will recruit 400 dyads of patients at high risk of death in the next year 
and their surrogates from 30 dialysis clinics in 4 states.  
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR ENDPOINT S 
Primary    
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   15 OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR ENDPOINT S 
Examine the effectiveness of SPI[INVESTIGATOR_644980] -of-life 
decision making (defined as dyad 
congruence on goals of care, patient 
decisional conflict, and surrogate 
decision -making confidence) at [ADDRESS_863449] -intervention.  
 
 Dyad congruence on goals of care 
(binary);  
Patient decisional conflict (scale);  
Surrogate decision -making confidence 
(scale)  
Composite outcome (goals -of-care 
congruence with confident surrogate ; 
binary)  The primary goal of SPI[INVESTIGATOR_644981] -of-life decision making. The 
preparedness outcomes will indicate 
whether or to what extent SPI[INVESTIGATOR_644982].  
Secondary    
Examine the effectiveness of SPI[INVESTIGATOR_644983]’ post -
bereavement distress  Anxiety symptom score (HAS -anxiety);  
Depression symptom score (HAS -
depression);  
Post -traumatic distress symptom score 
(PTSS)  
 Surrogate prepared by [CONTACT_645143][INVESTIGATOR_644984] -bereavement distress.  
Evaluate the process outcomes of 
SPI[INVESTIGATOR_644925]: during the 
initial and d elayed implementa tion of 
SPI[INVESTIGATOR_644985], fidelity, intervention costs, 
and sustainability  Descriptive aim to generate data for 
translation  
Tertiary/ Exploratory    
Examine the effectiveness of SPI[INVESTIGATOR_644986] (percentages of 
patients hospi[INVESTIGATOR_057], having ICU 
admission, and having intensive 
procedures, and LOS)  To examine whether SPI[INVESTIGATOR_644987] -
dementia intervention on the 
preparedness outcomes and care 
decisions  Dyad congruence on goals of care 
(binary);  
Patient decisional conflict (scale);  
Surrogate decision -making confidence 
(scale)  
Composite outcome (goals -of-care 
congruence with confident surrogate; 
binary)  
 
Care decisions (withdrawal from dialysis, 
Do-Not-Resuscit ate order, hospi[INVESTIGATOR_637212])  The primary goal of SPI[INVESTIGATOR_644988]-of-life decision making. The 
preparedness outcomes will indicate 
whether or to what extent SPI[INVESTIGATOR_644982].  
 
 
Care decisions will reflect the effects 
of SPI[INVESTIGATOR_644989] -of-life decision 
making.  
Estimate the effects of the SPI[INVESTIGATOR_61192] -
dementia intervention on surrogates’ 
post-bereavement distress  Anxiety symptom score (HAS -anxiety);  
Depression symptom score (HAS -
depression)  
 Surrogate prepared by [CONTACT_645143][INVESTIGATOR_644990] -bereavement 
distress . 
Supplement cohort study (non -clinical 
trial)    
Assess the effect of the pandemic on the stability of end -of-life care preferences and on our key outcom es (dyad 
congruence on goals of care, patient decisional conflict, and surrogate decision -making confidence).  
  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   16  
Measurement and data collection time points   
Outcome  Measure  Completed by  [CONTACT_645145] -of-Care Tool (2 end -of-life scenarios)     Baseline and [ADDRESS_863450] Scale (range, 1 -5)    Baseline and 2 wks  
Surrogate decision -
making confidence  Decision Making Confidence Scale (range, 0 -4)    Baseline and 2 wks  
Overall preparedness  Preparedness for End -of-Life Decision Making (range, 26 -
104)     Baseline and [ADDRESS_863451] -bereavement 
distress  HADS ( each subscale range, 0 -21) 
PTSS -10 (range, 10 -70)    Baseline and 3 mo. 
after patient death  
End-of-life care intensity  Percentages of patients hospi[INVESTIGATOR_057], having ICU 
admission, and having intensive procedures and length of 
hospi[INVESTIGATOR_644991]’s perceived acceptability (range, 7 -
28); 
Semi -structured interview  
    End of the initial 
implementation  
Patient & surrogate 
acceptability  Patient and surrogate acceptability (range, 10 -40 each)     2 wks  
Fidelity  SPI[INVESTIGATOR_644992]’s coverage of the SPI[INVESTIGATOR_644993];    
Brief patient and surrogate survey     SPI[INVESTIGATOR_644994] 2 wks  
Intervention costs  The actual time the care provider spent in carrying out 
SPI[INVESTIGATOR_61192], multiplied by [CONTACT_645146] (+benefits), plus costs 
of materials     End of the early 
implementation  
Sustainability  Brief semi -structured interview     End of [ADDRESS_863452] 9 -
month follow -up 
Delayed implementation process evaluation      
Care provider  
acceptability  Dialysis care provider’s perceived acceptability (range, 7 -
28); 
Semi -structured interview  
 
    End of the delayed 
implementation  
Fidelity  SPI[INVESTIGATOR_644992]’s coverage of the SPI[INVESTIGATOR_644995]     SPI[INVESTIGATOR_644996], multiplied by [CONTACT_645146] (+benefits), plus costs 
of materials     End of the delayed 
implementation  
Descriptors and potential covariates      
   Sociodemographics  Sociodemographic Profile     Baseline  for patients 
and surrogates   
   End of the initial 
implementation  for 
clinicians  
   Clinical characteristics  Medical Profile     Baseline  
   Clinic -level contextual  
      data  Contextual Data Collection Form     End of each 
implementation  
   Usual care  Documented AD completion on the Plan of Care form; 
presence of DNR, POLST, or MOST (from EMR)     Baseline and  6 mo.  
Pt, patient; Srgt,  surrogate; Pro, care provider  
Data collection highlighted in yellow is performed locally.  
  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   17  
For supplement aims:  
 
Measurement and data collection time points   
Outcome  Measure  Completed by  [CONTACT_645147][INVESTIGATOR_61192] -dementia     
Preparedness      
Dyad congruence  Goals -of-Care Tool (2 end-of-life scenarios)    Baseline and [ADDRESS_863453] Scale (range, 1 -5)   Baseline and 2 -3 days  
Surrogate decision -
making confidence  Decision Making Confidence Scale (range, 0 -4)   Baseline and 2 -3 days  
Overall preparedness  Preparedness for End -of-Life Decision Making (range, 26 -
104)    Baseline and [ADDRESS_863454] -bereavement 
distress  HADS ( each subscale range, 0 -21)   Baseline and [ADDRESS_863455] a dialysis clinic -level clu ster randomized trial with two groups, SPI[INVESTIGATOR_644997].  We will recruit 400 dyads of patients on chronic (“prevalent”) dialysis who are at high risk of 
death in the next year and their surrogate decision -makers (total 800 individuals) from 30 free -standing dialysis 
clinics in 4 states. The primary outcomes are patient and surrogate self -report preparedness for end -of-life 
decision making. The implementation evaluation data will be obtained throughout the study course. Upon patient 
death (anticipate 20%  of patients ; n = ~ 80 ), we will assess surrogates’ post -bereavement distress. Patient 
participation will end at 9 months  (to allow for obtaining Medicare claims data during the study period)  or death, 
whichever occurs first; surrogate participation will e nd at [ADDRESS_863456] -death 
follow -up. If patient is still living at 9 months, we will ask for an extension of follow up period to include 12 more 
months. Medicare claims data for end -of-life treatment intensity will be obtain ed quarterly. Clinics assigned to 
usual care will receive the delayed implementation, SPI[INVESTIGATOR_61192], in Year 4, Q1. This is a Phase III trial of an intervention 
that involves minimal risks and has proven to be efficacious, and thus no interim analysis is planned.   
 
For Supplement Aims:  
 
Consent
at the clinicBaseline
Preparedness 
outcomes
SPI[INVESTIGATOR_644998]-up
Preparedness 
outcomesRCare decisions 
(withdrawal
fromdialysis;
hospi[INVESTIGATOR_644999])1-2 weeks ~[ADDRESS_863457]-
bereavement 
distress
If patient dies
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   18  
We will use a randomized controlled trial design with two groups: SPI[INVESTIGATOR_61192] -dementia and usual care. From the pool 
of screened but excluded ESRD patients, we will recruit 30 dyads of patients with mild to moderate dementia and 
their surrogates. The groups will be stratified by [CONTACT_545] (white vs non -white). Patient and surrogate self -reported 
preparedness for end -of-life decision making will be measured at baseline and shortly after the intervention (by 
[CONTACT_645148] 2 -3 days) a s done in the pi[INVESTIGATOR_645000] -dementia. Additionally, we will review the patient’s 
medical record to examine care decisions at 6 months or after the patient’s death, whichever occurs first. In the 
case of patient death, we will also assess surrogates’  post -bereavement outcomes (anxiety and depression 
symptoms) at 1 month after the patient’s death. Based on previous research,13 we anticipate about 50% of the 
supplement sample will die within 12 months of enrollment. All data collection from study participants will be 
telephone -based.  
 
Supplement  cohort study:  
 
 
4.[ADDRESS_863458] clinical 
effectiveness while gathering information on implementation.62 Hybrid designs are increasingly used to expedite 
the sequential process, “efficacy to effectiveness to preliminary implementation63 and are recommended when 
there is strong evidence of the intervention effects and the intervention is low risk for participants.62. To maximize 
data on t he implementation process and sustainability, we chose a delayed intervention design65 in which clinics 
are rando mized either to implement SPI[INVESTIGATOR_645001] (i.e., initial implementation) or to 
maintain usual care for a comparison condition and then implement the intervention in Year 4 (i.e., delayed 
implementation). The delayed implementation gr oup will effectively serve as control for effectiveness evaluation. 
The process outcomes from the initial implementation of SPI[INVESTIGATOR_645002]. We anticipate that we will make clinic -specific adapt ations to improve implementation in 
the delayed implementation phase. Clinics in the delayed implementation phase will be evaluated on the process 
outcomes, which will provide data on the iterated version of SPI[INVESTIGATOR_645003]. The 
Clinics 
rando-
mizedSPI[INVESTIGATOR_645004] 
(T1)
(by 
[CONTACT_648])Follow-up 
at 2 
weeks
(T2)
(by 
[CONTACT_648])SPI[INVESTIGATOR_645005] 
I & II 
(in 
person)Monthly 
check-in 
call x 9 or 
more
(by 
[CONTACT_648])Parent study
(T3)
(by 
[CONTACT_648])Before March 13, 2020
Supplement  
study6 months 
after T3
(T4) 
(by 
[CONTACT_648])Consent for
supplement study
during monthly 
check-in callPatient 
death or 
study endAfter March 13
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   19 delayed implementation is more ethical than not providing SPI[INVESTIGATOR_645006].     
 
Virtually no trials are purely pragmatic or explanatory; based on the PRECIS Tool and key characteristics of 
pragma tic trials,66,67 the proposed study is more pragmatic than explanato ry in the pragmatic -explanatory  
continuum because it will include diverse patient populations, multiple heterogeneous settings,  few inclusion and 
exclusion criteria, and the comparison condition is a real -world alternative (i.e., usual care), not a placeb o. 
Further, the study is built around normal dialysis care operations as much as possible with flexible study protocols 
that minimize intrusion in daily work flow at the dialysis facilities. Of direct relevance to dialysis care, the 
intervention will be im plemented by [CONTACT_645149], such as nurses and social workers.  
 
For Supplement Aims:  
As in our previous studies of SPI[INVESTIGATOR_61192], we chose individual randomization  because intervention spi[INVESTIGATOR_645007]. The intervention will be delivered by a trained interventionist, not a care 
provider, in a private room at the clinic,  or virtually due to the COVID -19 pandemic,  and thus it is near ly 
impossible for care providers to obtain the knowledge and skill related to SPI[INVESTIGATOR_645008]. We 
chose race (white vs non -white) as a stratification factor  to ensure equal allocation of race to each condition to 
control for race as a c onfounding variable.49  
 
The follow -up time poi nt ([ADDRESS_863459] intervention)  is to evaluate the impact of SPI[INVESTIGATOR_645009]’s impaired ability to recall what was discussed 
during the SPI[INVESTIGATOR_645010]. We considered measuring the outc omes immediately following the intervention, but 
this would increase subject burden as SPI[INVESTIGATOR_645011]. The time point for care decision reviews ([ADDRESS_863460] intervention)  was chosen t o help maximize 
the number of patients whose conditions progress within the study period so that we can explore the impact of 
SPI[INVESTIGATOR_61192] -dementia on care decisions. As in earlier SPI[INVESTIGATOR_645012], we will use telephone -based data collection  to reduce participants’ travel 
burden.  
 
Supplement cohort study : 
We posit that reflexive decision -making in response to the pandemic could discount previously expressed 
preferences for end -of-life care, thereby [CONTACT_645150]. We postulate that such 
alterations in decisions may be more prevalent among patients and families who have not had ACP to explore 
own values and beliefs about end -of-life care (such as dyads in the control group in the parent study), and also 
among Blacks, a racial group that is thought to embrace more aggressive treatment at the end of life.[ADDRESS_863461] 60% of deaths even though Blacks represent only 
13.4% of the American population. We have an opportun ity to address these complicated but urgent questions 
about end -of-life decision making when people fear a dangerous virus and are alarmed about scarce lifesaving 
resources, such as ICU beds and ventilators.  
 
4.3 JUSTIFICATION FOR INTERVENTION  
 
The SPI[INVESTIGATOR_645013] a one -time advance care planning intervention that has been rigorously tested and has 
demonstrated its efficacy. The details about the intervention, including the rationale, are described above (2.2 
Background).  
 
4.4 END OF STUDY DEFINITION  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.[ADDRESS_863462] data collection.  
 
For Supplement Aims:  
We will review  the patient’s medical record to examine care decisions at 6 months or after the patient’s death, 
whichever occurs first. In the case of patient death, we will also assess surrogates’ post -bereavement outcomes 
(anxiety and depression symptoms) at 1 month a fter the patient’s death. Based on previous research,13 we 
anticipate about 50% of the supplement sample will die within 12 months of enrollment.  
 
Supplement cohort study:  
Completion of 6 month follow -up (T4) after T3.  
 
5 STUDY POPULATION  
 
5.1 INCLUSION CRITERIA  
 
Patient eligibility criteria:   
a) 18 years or older  
b) on either hemodialysis or peritoneal dialysis  
c) able to understand and speak English.  
 
Surrogate eligibility criteria : 
a) 18 years or older (to serve as a surrogate decision -maker, the individual must be an adult)  
b) being chosen by [CONTACT_11581] t.  
 
Roughly [ADDRESS_863463] SPI[INVESTIGATOR_645014].  
 
For Supplement Aims:  
 
Patient eligibility criteria:   
a) Receiving in -center hemodialysis  at Emory or UVA dialysis clinics.   
b) Diagnosed with dementia  of any etiology  (or those for whom their care providers, either MD or APRN, are 
suspi[INVESTIGATOR_645015]) with  having mild to moderate cogniti ve impairment based on a Montreal 
Cognitive Assessment (MoCA) score of 13 or higher ,54,55 or a Saint Louis University Mental Status (SLUMS) 
score of 21 or higher  (high school education) or 20 or higher  (less than high school education)56  
c) Able to understand and speak English  
d) A UBACC (decision -maki ng capacity screening test) score  11. Because dementia is largely under -
diagnosed in the clinical setting for patients with ESRD, to identify additional patients with possible 
dementia, a trained research assistant will administer the MoCA or SLUMS to pa tients who are suspected 
(by [CONTACT_645151]) of having dementia. MoCA or SLUMS will take about 10 minutes to complete.  
 
Surrogate eligibility criteria : 
a) 18 years or older (to serve as a surrogate decision -maker, the individual must be an adult)  
b) being c hosen by [CONTACT_102].  
 
 
For supplement cohort study:  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   21 Dyads who completed the parent study’s baseline (T1) and 2 -week follow -up (T2) before March 13, 
2020.  
 
5.2 EXCLUSION CRITERIA  
 
Patient exclusion criteria:   
a) lack of an available surrogate,  
b) too ill or cognitively impaired to participate based on clinicians’ judgment *,  
c) already enrolled in hospi[INVESTIGATOR_6125].  
 
Surrogate exclusion criterion:  
a) Those who cannot complete questionnaires due to physical or cognitive limitations will be excluded.  
 
For Supplement Aims:  
Patient exclusion criteria:   
a) lack of an available surrogate,  
b) uncompensated hearing deficits ,  
c) already enrolled in hospi[INVESTIGATOR_6125].  
 
*Patients who are excluded from the parent study will be considered  for the supplement study.  
 
5.[ADDRESS_863464] at the dialysis center, it is possible that patients provide written consent to 
participate in the study with the assumption that their surrogates would be willing to participate with them 
(however, patients cannot com plete the baseline without willing surrogates), and then the surrogate actually 
declines to participate. Because randomization occurs at the clinic level, not the individual level, these cases will 
be reported under “not eligible” with reason.  
 
5.5 STRATEGIES FOR RECRUITMENT AND RETENTION  
 
Recruitment and C onsent procedures:  
The dialysis care provider  who has been selected by [CONTACT_645152][INVESTIGATOR_645016] 
(so-called, “SPI[INVESTIGATOR_645017]”) in both groups will generate a list of patients each quarter who meet the 
inclusion criteria . Depending on the clinic’s structure and workflow, the care provider who determines patients 
meeting the se criteri a may not be the same care provider, i.e., SPI[INVESTIGATOR_645018].  
 
From this list, the care provider will then assess the patient’s willingness to meet with a recruiter from the 
research team. The recruiter will then approach willing patients during their  scheduled dialysis clinic appointment 
to explain the study purposes and procedures.  In a private room, w ritten consent will be obtained from the 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   22 patient  after the study is reviewed and understanding is established.  The recruiter will then provide the pat ient 
with a study brochure and encourage him/her to talk to the surrogate regarding the study within the next 2 -3 
days (to avoid a cold call). Several days later, the recruiter will telephone the surrogate to assess his/her 
willingness to participate. Usin g a Surrogate Verbal Consent script and form , the site coordinator will document 
time and date. Upon this  verbal consent, the research staff at the Emory Study Coordination Center  will 
conduct baseline data by [CONTACT_648].  For surrogates in the SPI[INVESTIGATOR_645019], the recruiter  (at each study 
site)  will schedule the first SPI[INVESTIGATOR_645020] [ADDRESS_863465] been 
consistent at approximately 84% despi[INVESTIGATOR_645021]’ focus on end -of-life, the requirement that both patient and 
surrogate participate, and long -term follow -up. We expect a similar if not higher consent rate because the study 
involves a shorter follow -up time and minimal data collection directly from patients and surrog ates. Based on our 
previous studies,18-20 we conservatively anticipate that 427 patients (20%) will be eligible and willing  to 
participate. To reach [ADDRESS_863466] to enroll 21 -22 dyads per cluster on average. These  clinics each accept 
10-70 new patients e ach year (total 700 additional patients), and thus our recruitment goal is readily achievable.  
 
To Maximize Participant Retention, strategies found effective in retaining dyads over 12 months (dropouts, 3.8%) 
in our efficacy trial20 will be used: we will  
a) obtain two backup contacts from each member of the dyad in the event that we cannot reach them by 
[CONTACT_645153]  
b) make confirmation phone calls 2 days prior to each follow -up 
c) make monthly check -in calls  
d) send holiday cards  
e) assign the same data collector whenever possible  
f) compensate each member of the dyad with gift cards ($15 at baseline, $15 at 2 weeks for the 
preparedness outcome assessment; $[ADDRESS_863467]-bereavement outcome assessment). 
Consistent with a pragmatic trial, participants will not be compensated for participating in the 
intervention.  The Emory Study Coordination Center will be responsible for disbursement.  
 
For Supplement Aims:  
Participant s will be recruited from the Emory dialysis centers and the UVA dialysis center s . First, patients who 
have been diagnosed with an early stage of dementia (mild to moderate) or are suspected of having cognitive 
impairment by a care provider will be referred by [CONTACT_645154]. The medical records of those patients will be 
reviewed to preliminarily determine eligibility by a research staff member. During the patient’s dialysis treatment 
session at the center, the patient’s care provider will gain permission for the staff member to explain the study. 
With the patient’s permission, the st aff member will approach the patient, briefly explain the study, obtain verbal 
consent to conduct the MOCA or SLUM S and UBACC screening . If the patient has met the criteria for both early 
stages of cognitive impairment and decision -making capacity, the res earch staff member will provide detailed 
study information and confirm his/her surrogate decision -maker. Written consent will then be obtained from the 
patient . The research staff member will obtain the name [CONTACT_645186] (or confirm wi th the 
medical record as necessary) and call the surrogate in 2 -3 days to assess the surrogate’s willingness to participate. 
Verbal consent will be obtained from the surrogate. At the time of surrogate consent, the staff member will 
schedule a telephone -based data collection session for baseline assessment in about 2 weeks.  
 
To minimize in -person contacts, we will screen patients remotely/via phone whenever possible. Patients who are 
deemed  eligible will be approached by a social worker during their dialysis treatment session  or by [CONTACT_645155]. Pat ients who agree to be 
contact[INVESTIGATOR_530], a research staff member will call the patient, briefly explain the study, obtain verbal consent to 
conduct the cognitive  screening  using the MoCA and UBACC .  Verbal consent will then be obtained from the 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   23 patient if screening occurred over the phone.  The research staff member will obta in the name [CONTACT_645187] (or confirm with the medical record as necessary) and call the surrogate in 2 -3 days to assess the 
surrogate’s willingness to participate. Verbal consent will be obtained from the surrogate. At the time of 
surrogate consent, the staff member will schedule a telephone -based data collection session for baseline 
assessment in about 2 weeks.  
 
For supplement cohort study:  
At the next monthly check in phone call (as part of the parent study protocol), the research staff member will 
proceed with the procedures for the parent study and then introduce the participant to the supplement study, 
including the purpose and procedures  and obtain verbal consent. After both members of the dyad have 
consented, the recruiter will schedule two data collection calls (T3 within 1 week and T4 at 6 months). If 
additional subjects are needed, we will contact [CONTACT_645156].  
 
To Maximize Participant Retention, we will  
a) obtain two backup contacts from each member of the dyad in the event that we cannot reach them by 
[CONTACT_645153]  
b) make confirmation phone calls 2 days prior to the baseline and/or the SPI[INVESTIGATOR_645010] (intervention group)  
c) make scripted monthly check -in calls  
d) send holiday cards  
e) assign the same data collector whenever possible  
f) provide transportation support ($20) for the SPI[INVESTIGATOR_645022] (intervention group)  
g) compensate each member of the dyad with gift cards ($ 20 at baseline ; $[ADDRESS_863468] -intervention follow -up; 
and surrogates who complete post -bereavement assessment will receive $30 at 1 month after the 
patient’s death ). 
For supplement cohort study,  each member of the dyad will receive an additional $20 at the completion 
of T3 and $[ADDRESS_863469] numbers or emails. Verbal Care Provider Informed Consent will be used in 
consenting  process. Survey/Interviews will be scheduled to be conducted over the phone or in person  at the 
convenience of the Care Provider.  There will be no compensation for care provider’s participation.  
  
 
 
6 STUDY INTERVENTION (S) 
 
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
 
6.1.1  STUDY INTERVENTION  DESCRIPTION  
 
SPI[INVESTIGATOR_645023]:  
All care providers responsible for SPI[INVESTIGATOR_645024]. All sessions will 
be conducted in a private room in the clinic. The goals of SPI[INVESTIGATOR_645025] -of-life 
preferences and to he lp surrogates understand the patient’s wishes and prepare for the surrogate role. SPI[INVESTIGATOR_645026] -to-face sessions with patient and surrogate together. These sessions may occur using teleconferencing 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   24 software (Zoom) when surrogate decision makers live  or work  outside a 50 -mile radius of patient’s clinic. We 
project the monthly caseload for SPI[INVESTIGATOR_645027] [ADDRESS_863470] session (~45 min.) , the care provider will assess the patient’s and surrogate’s cognitive, 
emotional, and spi[INVESTIGATOR_37312]/religious representations of the patient’s illness, prognosis, and end -of-life care. This will 
allow the care provider to provide individualized information about topi[INVESTIGATOR_1102], such as the effectiveness of life -
sustaining treatment for p eople with end -organ failure, and assist the patient to examine his/her values about 
life-sustaining treatment at the end of life. The care provider will help the surrogate prepare for end -of-life 
decision -making and for the emotional burden of decision -making by [CONTACT_645157]. If the surrogate is someone out of the order of the hierarchical compensatory model71 (e.g., a sibling is 
chosen instead of a spouse), the care provider will explore potential family conflicts and encourage the dyad to 
talk with other family members and complete a healthcare power of attorney. A Goals -of-Care document will be 
completed at the end of the session to indicate the patient’s preferences.   
A brief second session (~15 min.)  will be delivered about approximately [ADDRESS_863471] session. The patient’s Goals -of-Care document will be reviewed and 
assessed for the need for clarification or correction. The provider will document the patient’s end -of-life 
preferences and the surrogate’s name [CONTACT_645188]. If the patient desires 
a DNR order, POLST, or MOST, the care provider will discuss with the patient’s nephrologist and arrange a meeting 
to complete a treatment order form. We will track completion of these forms.  
 
For Supplement A ims:  the SPI[INVESTIGATOR_645028]’s limited or absent 
short -term memory.  During the COVID -[ADDRESS_863472], a full code is presumed. A social worker or charge nurse reviews 
code status and updates it annually. Currently, all four states endorse the physician orders for life -sustaining 
treatment (POLST) paradigm; NM MOST (medical orders for scope of tre atment), NC MOST, PA POLST, VA POST 
and GA POLST; these forms may be completed to complement ADs. None of the clinics employ routine 
identification of patients at high risk for death or structured ACP sessions targeting those patients.  
6.1.2  DOSING AND ADMINISTR ATION  
 
Described above (6.1.1) . 
 
 
6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY  
 
6.2.[ADDRESS_863473] SPI[INVESTIGATOR_644968] (e.g., ANP, RN, MSW). 
SPI[INVESTIGATOR_645029] 4 for 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   25 the delayed implementation clinics. The SPI[INVESTIGATOR_645030] s, trained and certified by [CONTACT_978] [INVESTIGATOR_645031] (at Emory), will conduct SPI[INVESTIGATOR_645032].  
 
Care provider training will consist of a 1½ -day, competency based program that has been used in our previous 
trials:  
• Module 1 (1/2 day) to ensure understanding of end -of-life care is sues and communication as key to 
improving end -of-life care and the Representational Approach (theoretical underpi[INVESTIGATOR_645033]);  
• Module 2 (1/2 day), as skill -base session to gain understanding of the SPI[INVESTIGATOR_645034], 
including role pl ays. A 2 -week practice period will be scheduled for integration of skills and exploration of 
additional learning needs; and  
• Module 3 (1/2 day) for skill -demonstration and certification. These training sessions will be conducted in 
collaboration with the E mory Nursing Professional Development Center . 
 
For Supplement Aims:  
An RN who has been trained and certified for SPI[INVESTIGATOR_61192] -dementia will deliver the intervention, who is currently 
working as the interventionist for the SPI[INVESTIGATOR_61192] -AD study (IRB #00099738).  SPI[INVESTIGATOR_645035] a 
private room at the dialysis center  or virtually with ZOOM . At the beginning, the interventionist will administer 
the MoCA or SLUMS (depending on which test was used at enrollment), which should take about  [ADDRESS_863474] will begin the SPI[INVESTIGATOR_645036]’s and surrogate’s cognitive, emotional, and 
spi[INVESTIGATOR_37312]/religious representations of the patient’s illness, prognosis, and end -of-life care. This will allow the 
intervent ionist to provide individualized information about topi[INVESTIGATOR_1102], such as the effectiveness of life -sustaining 
treatment for people with end -organ failure, and assist the patient to examine his/her values about life -sustaining 
treatment at the end of life. The in terventionist will help the surrogate prepare for end -of-life decision -making 
and for the emotional burden of decision -making by [CONTACT_645158]. If the 
surrogate is someone out of the order of the hierarchical compensato ry model59 (e.g., a sibling is chosen instead 
of a spouse), the care provider will explore potential family conflicts and encourage the dyad to talk with other 
family members and complete a healthcare power of attorney. A Goals -of-Care document will be completed at 
the end of the session to indicate the patient’s preferences. The delivery of SPI[INVESTIGATOR_61192] -dementia incorporates so -
called “enhanced consent techniques,” such as reducing information load by [CONTACT_645159], offering repetition of mat erial, opportunity for rehearsal, and using targeted questioning to verify 
adequate comprehension prior to eliciting preferences for goals of care.60-62 All sess ions will be audio -recorded 
and transcribed. At the end of the session, the dyad will receive $[ADDRESS_863475] STORAGE AND STABILITY  
 
Not applicable.  
 
6.2.4  PREPARATION  
 
Not applicable.  
 
6.3 MEASURES TO MINIMIZE BIAS : RANDOMIZATION  AND BLINDING  
 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   26 Clinics covered by [CONTACT_645160][INVESTIGATOR_645037]; this results in clusters ( 4 in GA, 3 in NC, 8 in NM, 5 in PA  and 8 in VA ). Because the numbers 
of available patients substantially vary across the clusters, to minimize group imbalance clusters will b e stratified 
to three sizes: small (patient census ≤ 52), medium (53 -105), and large (≥ 106). We will randomize clusters to 
either SPI[INVESTIGATOR_645038], with randomly permuted blocks (sizes of 2 and 4) within cluster 
size stratum nested  in each state, using a pseudo -random -number generator, by [CONTACT_645161].  
 
Before the study starts, the Study Coordination Center will inform the group assignment for each cluster to the 
site PIs, with a unique ID consisting of abbreviatio ns for state and cluster size stratum. While the heterogeneity in 
minority race/ethnicity across clusters improves the study’s generalizability, stratification or pairing clusters by 
[CONTACT_545]/ethnicity is not feasible because  some clinics uniquely serve one ra ce with no comparable clinics within state. 
Group imbalances on race/ethnicity and other potential confounding factors will be examined and adjusted for in 
the analyses. The cluster randomized design prevents blinding patient -surrogate dyads and dialysis c are providers 
to group allocation. However, research staff assessing effectiveness outcomes will be blind to group assignment.  
 
For Supplement Aims:  
[CONTACT_115280] (biostatistician/Co -I) will generate a randomization scheme using stratified (by [CONTACT_545]), permuted block 
randomization with block size 5, using a random -number generator. Dyads will be randomized with equal 
allocation (1:1) to SPI[INVESTIGATOR_644964]. Due to the nature of the intervention, blinding dyads to their group 
allocation is impossible, bu t the research staff assessing outcomes will be blind. Immediately after the completion 
of the baseline assessment by [CONTACT_648], the data collector will open a sealed envelope to identify group assignment 
and schedule an intervention session to take place ~2 w eeks hence for SPI[INVESTIGATOR_645039] a follow -up data 
collection session in the next 2 -3 days.  
 
6.4 STUDY INTERVENTION  COMPLIANCE  
 
To maintain internal validity, certain components of the intervention will be standardized: standardized care 
provider training using the training modules (described above); Session 1 will be delivered via face -to-face; the 
SPI[INVESTIGATOR_645040] u sed during each session to promote consistency and quality of intervention 
delivery. We will develop a template of procedures related to SPI[INVESTIGATOR_645041] a resource.  
 
To assess fidelity, we will use two indepen dent data sources.   
1) The SPI[INVESTIGATOR_645042] -surrogate dyad encounter (the data will be entered into REDCap by [CONTACT_645162]). The 
Guide has a checklist of SPI[INVESTIGATOR_645043], including start and finish times and brief self -evaluation.  
2) At the [ADDRESS_863476] 50 dy ads (~first 4 months) 
have been seen, clinics with <80% adherence on both data sources will receive feedback and another 
orientation meeting by [CONTACT_7910] [INVESTIGATOR_645044].  
 
We considered replacing clinics with <80% adherence, but this approach would not be consistent with the 
pragmatic nature of the study to test SPI[INVESTIGATOR_645045] a real -world setting.  We also considered recording a sample of 
SPI[INVESTIGATOR_644968], but this approach would likely be considered intrusive by [CONTACT_645163] a pragmatic trial.  
 
For Supplement Aims:  
To promote consistency and quality of intervention delivery, the SPI[INVESTIGATOR_645046]. To monitor fidelity, we will use two data sources. 1) The SPI[INVESTIGATOR_645047] -surrogate dyad encounter; these data will be 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   27 entered into the Research Electronic Data Capture (REDCap) by [CONTACT_23164]. The Guide has a 
checklist of SPI [INVESTIGATOR_645048], including start and finish times, and brief self -evaluation. 2) All intervention 
sessions will be audio -recorded. Every 2 months, 50% of sessions randomly selected will be reviewed by [CONTACT_978]. 
Using the Treatment Fidelity Assessment Tool, th e interventionist’s adherence to intervention content, process, 
and duration will be evaluated on a 3 -point scale (1=appropriate, 3=skipped). Problems detected including drift 
from protocol will be discussed with the interventionist and re -training will be  provided if adherence is <80% 
based on the Fidelity Assessment Tool.  
 
6.5 CONCOMITANT THERAPY  
 
Not applicable  (all patients receive usual care related to advance care planning).  
 
6.5.1  RESCUE MEDICINE  
   
Not applicable.  
 
7 STUDY INTERVENTION  DISCONTINUATION  AND PARTICIPANT  
DISCONTINUATION /WITHDRAWAL  
 
7.1 DISCONTINUATION  OF STUDY INTERVENTION  
 
SPI[INVESTIGATOR_644956] a one -time intervention  with two sessions . If patient -surrogate dyads is not able to complete Session  I or 
II, the reason or circumstances (e.g., the patient became too ill) will be documented and reported. Session II 
cannot be offered without Session I completed; that is, it is possible that a patient -surrogate dyad completes 
Session I but not Sess ion II. Dyad s who  never complete Session I and dropout will be replaced by [CONTACT_79323] a new 
dyad.   
 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE STUDY  
 
Participant s are free to withdraw from participation in the study at any time upon request.  
An investigator may discontinue  or withdraw a participa nt from  the study for the following reasons : 
• If the participant  meets an exclusion criterion that precludes further study participation . 
 
The reason for participant discontinuation  or withdrawal from the study will be rec orded on the study REDCap . 
Subjects from the dialysis center randomized to initial SPI[INVESTIGATOR_645049].  Subjects in the initial SPI[INVESTIGATOR_645050] , and subsequently withdraw, or are withdrawn or discontinued  from the study 
will not be replaced.  
 
7.[ADDRESS_863477] to follow -up if he or she fails to complete the scheduled 2 -week 
follow -up (after the receipt of the intervention) and is unable to be contact[CONTACT_645164] [ADDRESS_863478] to follow -up if h e or she fails 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   28 to complete the scheduled 3 -month follow -up (after the patient’s death) and is unable to be contact[CONTACT_645165] .  
 
The following actions must be taken if a participant is determined to be lost to follow -up: 
• The site will attempt to contact [CONTACT_645166] 4 weeks  and 
ascertain if the participant wishes to continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee will make every effort to 
regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if necessary, a certified letter 
to the participant’s last known mailing address or local equivalent methods , or speak to the patient at the 
dialysis center ). These contact [CONTACT_103904] s will be documented in the participant’s record in REDCap .  
• Should the participant  continue to be unreachable, he or she will be considered to have withdrawn from 
the study with a primary rea son o f lost to follow -up. 
 
8 STUDY ASSESSMENTS AND PROCEDURES  
 
8.1 OUTCOME  ASSESSMENTS  
 
Collecting effectiveness outcome data will be centralized; research staff at the Study Coordinating Center will 
collect the data from patients and surrogates by [CONTACT_648]. Telephone -based collection minimizes participants’ tra vel 
burden. Centralized data collection maintains data collectors being blind to group assignment. The preparedness 
outcomes will be assessed at [ADDRESS_863479] roughly 40% of study 
patients (~160) to die by [CONTACT_941] 9 -month follow -up; deaths are readily identifiable through dialysis clinics and will 
trigger post -bereavement surveys with surrogates at [ADDRESS_863480] -bereavement and then stabilized at 3 months.  
 
Effectiveness Outcomes  
Preparedness for end -of-life decision making (measured at baseline and [ADDRESS_863481] -Session II) :   
• Dyad congruence  will be assessed using the Goals -of-Care Tool,18,[ADDRESS_863482], the patient develops a 
severe complication and cannot speak for himself/herself; the medical team believed recovery unl ikely 
and continuing life -sustaining treatment, including dialysis, would no longer be beneficial. In the second 
scenario, the patient develops advanced dementia. Each scenario has three response options: “The goals 
of care should focus on delaying my deat h, and thus I want to continue life -sustaining treatment”, “The 
goals of care should focus on my comfort and peace, and thus I do not want life -sustaining treatment, 
including dialysis”, and “I am not sure”. Patients and surrogates complete this tool indep endently and 
their responses are then compared to determine dyad congruence -- either congruent in both scenarios 
or incongruent. If both members of the dyad endorse “I am not sure”, they are considered incongruent.   
• Patient decisional conflict  will be measured using the [ADDRESS_863483] Scale (DCS), a validated 
measure in the context of end -of-life decision making17; higher sc ores indicate greater difficulty in 
weighing benefits and burdens of life -sustaining treatments and decision making (range 1 -5; Cronbach’s  
= 0.8 – .9317,18,20,72).  
• Surrogate decision -making confidence  will be measured using the 5 -item Decision Making Confidence 
(DMC) scale (Cronbach’s  = 0.81 -0.9018,34) on which higher scores reflect greater comfort in performing 
as a surrogate (range 0, not confident at a ll-4, very confident). DMC is a self -report of a surrogate’s 
confidence in: knowledge of the patient’s wishes, ability to make treatment decisions even in a highly 
stressful situation, ability to seek information about risks and benefits of medical choices , ability to handle 
unwanted pressure from others, and ability to communicate with health care providers about the 
patient’s wishes.  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   29 • Composite outcome : We will also create a composite outcome combining dyad congruence and surrogate 
DMC to differentiate su rrogates who understand the patient’s wishes and feel confident in their role from 
those who don’t (understand the wishes but lack confidence, misunderstand the wishes but feel 
confident, neither understand nor feel confident).18,34  
• We will also assess the overall preparedness for end -of-life decision making  using the 26 -item 
investiga tor-developed measure. The measure assesses the level of preparedness for end -of-life decision 
making in the cognitive, emotional, and behavioral dimensions on a 4 -point scale (4=strongly agree to 
1=strongly disagree) with higher scores indicating higher l evels of preparedness. Patient and surrogate 
each will complete this measure separately.    
 
During the supplement cohort study , the participating dyads will complete the same measures above twice, at 
enrollment and 6 months after.   
In addition, they will complete the COVID -19 Stress Scale. COVID -19 Stress Scale35 is a 35 -item measure to assess 
pandemic rel ated emotional responses (i.e., COVID -19 stress and anxiety symptoms) on a 5 -point scale ranging 
from 0 (not at all) to 4 (extremely). The subscales are (1) danger and contamination fears, (2) fears about 
economic consequences, (3) xenophobia, (4) compulsi ve checking and reassurance seeking, and (5) traumatic 
stress symptoms about COVID -19. The scale has demonstrated excellent internal consistency reliability 
(Cronbach’s >.8 for all subscales) and convergent and discriminant validity. We will also add an o verall rating  to 
assess how much respondents worry about COVID -19, which recently was used by [CONTACT_38874] .,36 “Please rate the 
level of your current worry toward COVID -19” on a scale ranging from 1 (very mild) to 10 (very severe).  
 
Surro gates’ post -bereavement psychological distress (at baseline and [ADDRESS_863484] patient death) :   
Symptoms of anxiety, depression, and post -traumatic distress42,73 will be measured using the Hospi[INVESTIGATOR_58900] (HADS)74; subscale scores range from [ADDRESS_863485] reliabilities are 0.88 –0.90 and 0.84 –0.94, respectively.[ADDRESS_863486] -Traumatic Symptoms Scale -10 (PTSS -10).76 
Higher scores indicate more intense symptoms (range 10 -70).[ADDRESS_863487] completed the SPI[INVESTIGATOR_644968] (~Year 3, Q1), care 
providers will complete a survey and an interview.  
• Care provider acceptability will be evaluated using the 7 -item Care Providers’ Perceived Acceptability 
Survey to assess their  perceptions about SPI[INVESTIGATOR_644925], including the time required, impact on 
interactions with patients, and whether they would recommend SPI[INVESTIGATOR_645051].80  Response 
options range from 1=strongly disagree to 4=strongly agree; higher scores indicate greater acceptability.  
• A brief (~15 min.) semi -structured interviews (face -to-face or by [CONTACT_756]; audio -recorded) will obtain 
provider s’ perspective s on whether the implementation of SPI[INVESTIGATOR_645052], it’s perceived utility, their willingness to continue using it after the study, factors influencing 
implementation (barriers, logistical constraints,  and facilitators), and suggestions for improvement.  
• Patient and surrogate acceptability  will be assessed using the 10 -item ACP Acceptability  Questionnaire 
developed from our previous trial,24  Participants are asked how strongly they agree or disagree  (4 to 1) 
with statements about their experience with SPI[INVESTIGATOR_644968], including duration, interactions with the 
care provider, level of comfort and satisfaction. H igher  scores indicate greater acceptability. Each patient 
and surrogate will complete this survey at the [ADDRESS_863488] -intervention follow -up.  
• Fidelity/adherence  will be assessed using two independent data sources, (a) the SPI[INVESTIGATOR_645053], 
Checklist, and self-evaluation completed by [CONTACT_645167][INVESTIGATOR_645054] (b) patient and 
surrogate responses to the SPI[INVESTIGATOR_645055] [ADDRESS_863489] -intervention follow -up as 
described above. The number of SPI[INVESTIGATOR_645056], th e minutes required for the care provider 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   30 to complete the sessions, the number of dyads who complete SPI[INVESTIGATOR_644968], and the number of 
incomplete or interrupted sessions will be aggregated.  
• Intervention cost s will be estimated based on the actual time the  care provider spent in carrying out 
SPI[INVESTIGATOR_61192], multiplied by [CONTACT_645146] (+benefits), plus costs of materials. Overhead (e.g., facility) costs and 
research staff’s time will not be included.  
• We define sustainability  as the extent to which a newly implemente d intervention is maintained within a 
service setting’s ongoing, stable operations.[ADDRESS_863490] a brief interview with SPI[INVESTIGATOR_645057] s to ask about sustainability: (a) Is SPI[INVESTIGATOR_645058] -going (and at what frequency)? (b) What 
components of the SPI[INVESTIGATOR_645059]? and (c) Has SPI[INVESTIGATOR_645060]? If so, how?[ADDRESS_863491] ended at the end of 9 -month follow -up or patient death. Care provider 
acceptability, fidelity, and intervention costs will be determined as described above.  
 
End-of-life treatment intensity (upon patient death)   
We will link study data to publicly available USRDS data. The USRDS captures inpatient and outpatient Medicare 
claims on all treated U.S. ESRD patients and releases these data annually free of charge. Medicare claims data are 
the most complete and reliable source of data on end -of-life care intensity because patients on dialysis are 
Medicare beneficiaries. The USRDS data are far superior to that which could be obtained through individual 
hospi[INVESTIGATOR_645061]. From 
the inpatient and outpatient claims data, we will obtain dates and attributed causes of death; dates of hospi[INVESTIGATOR_307], 
skilled nursing facility, and hospi[INVESTIGATOR_645062]; dates of outpatient encount ers (including dialysis 
sessions and ED visits); and diagnostic and procedure codes for all inpatient and outpatient encounters. Thus, we 
will be able to determine  hospi[INVESTIGATOR_059], ICU days, days hospi[INVESTIGATOR_057], use of intensive procedure, 
(dis)continuation of dialysis (also from CMS Form 2746), and hospi[INVESTIGATOR_645063]. We will 
consider the following to be intensive procedures: mechanical ventilation, feeding tube placement, dialysis, and 
cardiopulmonary resuscitation.22 These intensive procedures will be identified using HCPCS and ICD -9-CM codes 
(e.g., ICD -9 codes for intubation and mechanical ventilation: 96.04, 96.05, 96.7X).83  
 
Descriptors and Potential Covariates  
• Patients and surrogates will complete a Sociodemographic Profile  which includes age, gender, race and 
ethnicity, type of relationship between patient and surrogate, marital status, religious affiliation, 
education, household income, previous end -of-life decision -making experience, and previous participation 
in an ACP d iscussion or AD completion.  
• To describe the sample, the patient’s clinical characteristics , including dialysis modality, years on dialysis, 
comorbid conditions will be abstracted from the patient’s EMR.  
• Care providers’ sociodemographic data  will include age, gender, race and ethnicity, education, and years 
of practice.  
• At baseline, we will collect clinic -level contextual data84 that could facilitate understanding study results, 
including staffing, patient census, rural -urban status,85-89 palliative care and hospi[INVESTIGATOR_645064], and 
proximity of hospi[INVESTIGATOR_600].  
 
For Supplement Aims,  
 
• The preparedness outcomes measures will be assessed at baseline and 2 -3 days after the intervention.  
• Surrogates’ post -bereavement psychological distress will be assessed using the HADS, which will be 
completed at baseline and [ADDRESS_863492] patient death.  
• Patients’ level of articulation of end -of-life wishes:  Using a “quantitizing” technique of qualitative data 
analysis,39 two raters will independently review SPI[INVESTIGATOR_645065] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   31 treatment outcomes and the goals of care discussions and rate the level of patient’s articulation of end -
of-life care preferences on a 3 -point scale  (3=expressed wishes very coherently, 2=somewhat coherently, 
1=unable to express wishes coherently). Inter -rater reliability (percent agreement) will be established, 
targeting  90%.  
• Care decisions (assessed at [ADDRESS_863493] intervention or after the patie nt’s death, whichever occurs 
first):  Stoppi[INVESTIGATOR_645066], DNR order, and hospi[INVESTIGATOR_645067] (or APRN) and social worker. These decisions are also required to be documented in the 
CMS Form 2746 in the event of a dialysis patient’s death. On a monthly basis, the research coordinator  
will check in with the outpatient dialysis APRN to track these care decisions and will be aggregated at 6 
months.  
• Descriptors and Potential Covariates (collected at baseline): Patients and surrogates will each complete a 
Sociodemographic Profile  which in cludes demographic information and previous end -of-life decision -
making experience. Patients’ clinical characteristics  (e.g., date of dementia diagnosis, etiology of 
dementia, and comorbid conditions) will be abstracted from the patient’s medical records.  
 
8.2 SAFETY AND OTHER ASSESSMENTS  
 
SPI[INVESTIGATOR_644956] a one -time psychoeducational intervention. The  study involves very low risk and the  potential risk may 
include fatigue or emotional upset during the session.  
 
Fatigue  
 
As part of outcome assessment, HADS and PTSS -10 will be completed. Although these measures  are not 
diagnostic tools, if a surrogate’s HADS -Depression is high ( ≥ 15), the data collector will  ask the surrogate if she/he 
is aware of the mood state and encourage to speak to his/her primary care provider . If a surrogate expresses 
suicidal  ideation , the data collector will immediately notify the local site coordinator who wi ll confer with the Site 
PI. This Site PI [INVESTIGATOR_645068] (during hours) or the 24 -hour Emergency 
Psychiatry Service (after hours) for evaluation of mental health or emergency intervention is necessary.  
   
8.3 ADVERS E EVENTS AND S ERIOUS ADVERSE EVENTS  
 
8.3.1  DEFINITION OF ADVERSE EVENTS  (AE)  
 
SPI[INVESTIGATOR_644956] a one -time psychoeducational intervention. The study involves very low risk and the potential risk may 
include fatigue or emotional upset during the session , neither of which is a “medical occurrence” . SPI[INVESTIGATOR_645069]. T he present trial is to generate data 
to accelerate translation of the intervention into clinical practice.  
 
8.3.2  DEFINITI ON OF SERIOUS ADVERSE EVENTS  (SAE)  
 
The trial targets ESRD patients on dialysis who already have serious life -threatening medical conditions and are 
likely to die within a year (by [CONTACT_30223]’s judgment). SPI[INVESTIGATOR_645070] -of-life decision making. SPI[INVESTIGATOR_61192]’s safety and beneficial effects (e.g., 
reducing psychological distress) have been consistently demonstrated. Participants’ deaths or hospi[INVESTIGATOR_602] (or 
other events descr ibed above) during the trial are expected (and needed to answer the scientific questions) and 
will occur as part of the illness course. These events will not be considered as SAE in this trial.  However, any 
participant’s death will be reported to IRB throu gh annual progress report and included in the NIH annual 
progress report.   
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   32  
8.3.3  CLASSIFICATION OF AN ADVERSE E VENT  
[IP_ADDRESS]  SEVERITY OF EVENT  
 
Not applicable.  
 
 
[IP_ADDRESS]  RELATIONSHIP TO STUDY INTERVENTION  
 
Not applicable.  
 
[IP_ADDRESS]  EXPECTEDNESS  
 
There are no known expected adverse reactions. SPI[INVESTIGATOR_645071] [ADDRESS_863494] been observed in the previous studies. Thus, these reactions are very unlikely to occur and will be 
considered “unexpected.” Intervention sessions will stop if any of these events occurs.   
8.3.4  TIME PERIO D AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
 
Not applicable.  
 
8.3.5  ADVERSE EVENT REPORTING  
 
The possible adverse reactions (fatigue, emotional distress during the intervention session), if ever occurs, will be 
tracked (documented in the study REDCap) and the aggregated numbers will be reported at the upcoming 
biannual DSMB meeting.  
 
Any disease -related events (DREs) common in the study population (e.g., expected) such as death will not be 
reported per the standard process of reporting but will be monitored so that surrogates’ post -bereavement 
outcomes and end -of-life treatment intensi ty data (Medicare claims data) can be collected timely.  However, any 
participant’s death will be reported to IRB through annual progress report and included in the NIH annual 
progress report.   
 
8.3.[ADDRESS_863495]  
 
Not applicable.  
 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.[ADDRESS_863496] SAFETY  
 
Any unexpected problem related to the Research that negatively affects the rights, safety or welfare of subjects 
and is not described as such in the materials describing risks associated with the study.  
 
8.4.1  DEFINITION OF U NANTICIPATED PROBLEMS (UP)  
 
Unanticipated problems are defined by [CONTACT_32119] 45 CFR part 46 as any incident, experience, or outcome that meets 
all of the following criteria:  
• unexpected, in terms of nature, severity, or frequency, given (a) the research procedures that are 
described in the protocol -related documents, such as the IRB -approved research protocol and informed 
consent document; and (b) the characteristics of the study population;  
• related or possibly related to participation in the research (in this guidance document, possibly re lated 
means there is a reasonable possibility that the incident, experience, or outcome may have been caused 
by [CONTACT_3459]);  
• suggests that the research places participants or others at a greater risk of harm (including physica l, 
psychological, economic, or social harm) than was previously known or recognized.  
It will be extremely unlikely in this study that the events of fatigue and emotional distress would meet the all of 
the criteria above.  
 
8.4.2   UNANTICIPATED PROBLEM REPORTING  
 
If we encounter an y adverse event that meets the definition  above and that is related to the intervention, the PI 
[INVESTIGATOR_645072] 24 hours of the event being reported to 
the PI. The expedited report will be followed by a detailed, written SAE report as soon as possible.  
 
8.4.3  REPORTING UNANTICIPATED PROBLEMS  TO PARTICIPANTS  
 
Not applicable.  
 
9 STATISTICAL CONSIDERATIONS   
 
9.1 STATISTICAL HYPOTHESES  
 
• Primary Endpoint(s):  
1) The number of SPI[INVESTIGATOR_645073] [ADDRESS_863497] -intervention will be 
significantly higher than that of control dyads.  
2) Patient decisional conflict scores at [ADDRESS_863498] -intervention will be significantly lower than those of 
control dyads.  
3) Surrogate decision mak ing confidence (DMC) scores at [ADDRESS_863499] -intervention will be significantly 
higher than those of control dyads.  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   34 4) The number of SPI[INVESTIGATOR_645074] (DMC=3 or 
higher) at [ADDRESS_863500] -intervention will be significantly higher than that of control dyads.  
 
• Secondary Endpoint(s):  
1) HAD -anxiety scores in SPI[INVESTIGATOR_645075] 
3 months after the patient’s death.  
2) HAD -depression scores in SPI[INVESTIGATOR_645076] 3 months after the patient’s death.   
3) PTSS -10 scores in SPI[INVESTIGATOR_645075] 3 
months after the patient’s death.  
 
• Explora tory: Among patients who have died,  
1) The percentage of patients hospi[INVESTIGATOR_645077].  
2) The percentage of patients admitted to an ICU during the final month of life in the SPI[INVESTIGATOR_645078].  
3) The percentage of patients having intensive procedures during the final month of life in the SPI[INVESTIGATOR_645079]. 
4) The length of hospi[INVESTIGATOR_645080].  
 
For Supplement Aims:  
• Aim 1:  
1) The number of SPI[INVESTIGATOR_645073] [ADDRESS_863501] -intervention will be 
higher than that of control dyads.  
2) Patient decisional conflict scores at [ADDRESS_863502] -intervention will be lower than those of control 
dyads.  
3) Surrogate decision -making confidence (DMC) scores at [ADDRESS_863503] -intervention will be higher  than 
those of control dyads.  
4) The number of SPI[INVESTIGATOR_645074] (DMC=3 or 
higher) at 2-[ADDRESS_863504] -intervention will be significantly higher than that o f control dyads.  
5) The proportion of decisions made at 6 months ( e.g. stoppi[INVESTIGATOR_645066], DNR order, and hospi[INVESTIGATOR_645081].) follow -up or death of patient will be higher in the intervention dyads than that of 
control dyads.  
 
• Aim 2:  
1) HAD -anxiety scores in SPI[INVESTIGATOR_645082] n those of control surrogates at 1 month 
after the patient’s death.  
2) HAD -depression scores in SPI[INVESTIGATOR_645083] 1 months 
after the patient’s death.  
 
Supplement cohort study:  
Aim 1. Changes in patient’s goals of care preferences over time (T2 -T3 and T2 -T4) in the intervention group will be 
smaller than those in the control group.  
Aim 2. Changes in the preparedness outcomes over time in the intervention group will be smaller than those in 
the con trol group.  
Aim 3. The COVID -19 Related Stress and race/ethnicity will be significantly associated with changes in goals of 
care stability and the preparedness outcomes.  
 
 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.[ADDRESS_863505] 
clinically meaningful differences between 
SPI[INVESTIGATOR_645084]. Statistical power is based on a 
random effects models: a generalized linear 
mixed model for binary outcomes (e,g., dyad 
congruence) and a linear mixed model for 
continuous outcomes (e.g., patient decisional 
conflict).  
 
We conducted a simulation study to estimate 
power with 2 -sided significance level 
alpha=.05, corrected for anticipated dropout 
and potential intraclass correlations (ICCs) 
ranging .[ADDRESS_863506] sizes 
observed at 2 months20 rather than those at 2 
weeks,18 which are larger (e.g., for the composite outcome, OR=1.8 at 2 mon ths, OR=4.4 at 2 weeks). The overall 
power to detect clinically meaningful differences is excellent for the primary outcomes and good for the post -
death outcomes.  
 
For Supplement Aims:  
Because this is a pi[INVESTIGATOR_799], prior estimates of effect sizes were not available; thus a traditional sample size 
calculation was not performed. Instead we focused on calculating the minimum effect size that can be detected 
with adequate power (>=80%). Based on preliminary calculations, we found that a sample size of 30 wi ll achieve 
80% power to detect an effect size (Cohen’s f2) of 0.28 (moderate -high), attributable to the treatment group 
indicator using an F -test at a 5% significance level. We will use the estimates of effect sizes obtained from this 
study for sample size  calculations in future larger studies.  
 
Supplement cohort study:  
Due to the exploratory nature of the study, a traditional sample size calculation was not performed. Instead, our 
goal was to provide estimates of effect sizes (standardized mean differences  between pre - and during - COVID -19 
study points) for the outcomes in aims [ADDRESS_863507], indicate 
that a sample size of 72 in the SPI[INVESTIGATOR_645085] 35 in the usual care group achieve 80% power to det ect a 
difference in mean changes of 0.[ADDRESS_863508] deviation of 1.0 at both time points, a between measurement correlation of 0.2 and a 5% significance 
level . 
 
9.3 POPULATIONS FOR ANALYSES  
 
Patient -surrogate dyads will be the primary unit of analysis; all analyses will be intent to treat with all available 
data from all participants.  
 
9.4 STATISTICAL ANALYSES  Power for comparing SPI[INVESTIGATOR_645086] 19 clusters  
 
 
Aim 1  Percent or 
min. 
difference  OR or 
variance  ICCa Estimated 
power  
Dyad congruence  48%  OR=2.0  0.02  0.92  
0.04  0.84  
Patient DCS  d=0.24  0.23  0.01  0.98  
0.10  0.81  
Surrogate DMC  d=0.22  0.20  0.01  0.99  
0.10  0.80  
Composite 
outcome  47%  OR=2.0  0.02  0.93  
Aim 3      
Anxiety  d=1.35  7.0 0.01  0.84  
0.03  0.80  
Depression  d=1.60  10.0  0.01  0.85  
0.03  0.79  
PTSS -10 d=4.75  90.0  0.01  0.85  
0.03  0.78  
a observed ICCs in our prior work; d=1/[ADDRESS_863509] scale; DMC, decision -making confidence.  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.[ADDRESS_863510] descriptive statistics and graphical 
displays or frequency tables. Distributional assumptions will be assessed and the data will be transformed as 
necessary. Clinic characteristics ( e.g., rural -urban status) will be compared using 2 tests for categorical variables 
and t -tests for continuous variables. We will compare SPI[INVESTIGATOR_645087] (e.g., age, race/ethnicity) to explore possible between -group differences using generalized 
estimating equation (GEE) methods, accounting for the observed correlation within the same cluster.90,[ADDRESS_863511] on patient mortality20; however, we will compare survival time between SPI[INVESTIGATOR_645088], adjuste d for cluster effects. If imbalanced, we will consider 
adjustment for the group difference.  
 
9.4.2  ANALYSIS OF THE PRIMARY ENDPOINT(S)  
 
SPI[INVESTIGATOR_645089] : Dyad congruence and the composite outcome (binary 
variables) will be analyz ed by [CONTACT_6486] a generalized mixed effects model for each, where the binary outcome is 
modeled in terms of a logit link90 with both a random intercept and random slope to control for variation within 
and between subjects and clu sters. The model also includes the intervention SPI[INVESTIGATOR_61192], cl uster size and their 
interaction. For patient DCS and surrogate DMC scores, we will replace the logit link by [CONTACT_645168]. These models will allow us to examine whether SPI[INVESTIGATOR_645090] [ADDRESS_863512] of SPI[INVESTIGATOR_645091]. The analysis will be adjusted 
for potential covariates, such as race/ethnicity, and rural -urban status, in the model, including interaction 
between treatment and race/ethnicity.  
 
For Supplement Aims:  
To account for small sample size, resampling methods will be used for all analyses and 95% bootstrap confidence 
intervals of the differences in outcome scores will be reported.  
 
1) Aim 1 . SPI[INVESTIGATOR_645092] : For testing the effect of the intervention on dyad 
congruence, a paired binary outcome (congruent or not congruent), Mcnemar’s test will be used. In addition, a 
logistic regression model will be used to test for differences in post -intervention outcomes by g roups after 
adjusting for potential covariates. The adjusted ratio of odds of congruence in the intervention group versus the 
control group will be evaluated and reported as an effect size estimate.  
 
2) Aim 1 . SPI[INVESTIGATOR_645093]:  Differences  in proportion of decisions made (e.g. stoppi[INVESTIGATOR_645066], 
DNR order, and hospi[INVESTIGATOR_645094].) at [ADDRESS_863513] size. We will also explore time to event analysis to assess the di fference in rate of risks between 
the two groups using non -parametric and semiparametric methods.  
 
3) Aim 2. Surrogate post -bereavement distress (HADS scores): Differences in the HADS subscale scores between 
the intervention and control groups will be asse d using t -tests. Because, we estimate a 50% rate of death during 
the study, the number for this analysis would be n=15. A standardized difference between groups will be used as 
an effect size estimate.  
 
4) Aim 3 . Relationships among patients’ cognitive sta tus, decision -making capacity and their ability to express 
end-of-life wishes:   For patients in the SPI[INVESTIGATOR_645095] (n=15), associations between patients’ cognitive 
status (continuous), decision -making capacity (continuous) and their ability to exp ress end -of-life wishes 
(categorical) will be analyzed using one -way analysis of variance (ANOVA). We will also explore ordinal logistic 
regression to obtain the proportional odds ratios defined by [CONTACT_645169] “expressing wishes very coherently” or 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   37 “expres sing wishes somewhat coherently” versus the odds of “unable to express wishes coherently” for a unit 
increase in cognitive status or decision -making capacity.  
 
Supplement cohort study:  
As in the parent R01, we will use the Research Electronic Data Capture (REDCap) to create and update study 
participants’ data. During data entry, automated checks will be performed that will immediately flag problematic 
data (e.g., missing, out of range, inconsistent). Preliminary analyses will include summarizing var iables with 
descriptive statistics and graphical displays. We will assess distributional assumptions of the outcomes and apply 
appropriate transformations to remedy any violations. Any differences in patient characteristics (e.g. age, sex, 
education level,  household income) across groups will be adjusted when modeling the outcomes. As observed in 
the parent R01 (< 1% missing data), we expect very little missing data. Nonetheless, we plan to use restricted 
maximum likelihood (REML) method for estimating the repeated measures analysis to minimize the impact of 
missing data. This will make it possible to retain cases with partial data while making less restrictive assumptions 
about missing data patterns.  
Aim 1.  Compare the stability of patients’ goals -of-care preferences over time, from pre -outbreak to during -
outbreak, by [CONTACT_645170]:  We will use mixed effects modeling to assess differences in 
patients’ goals of care over time, from pre - to post -lockdown time points. We will sequentially build a longitudinal 
model that will include time, treatment group and race as fixed effects; then [ADDRESS_863514] parsimonious model using Akaike information criterion (AIC) and Bayesian information 
criterion (BIC). We will use contrasts to test whether participants demonstrated significant change in goals -of-care 
preferences across diff erent combinations of treatment and race.  
Aim [ADDRESS_863515]:  We will perform analyses similar to those described in Aim 1. In addition, fo r 
non-normal outcomes (binary, count) a generalized mixed effects model will be used. Appropriate contrasts will 
be used to assess differences in the outcomes over time by [CONTACT_6660], race and groups x race.  
Aim 3.  Examining the associations of the C OVID -19 Related Stress, sex, race/ethnicity, and other 
sociodemographic characteristics to the level of changes in the preparedness outcomes and patient’s goals -of-
care preference stability: We will use analysis of covariance to assess the relationship bet ween COVID -19 related 
stress and changes in outcomes from T2 to T3 and T3 to T4, after controlling for the corresponding baseline values 
of the outcomes (i.e., T2 and T3 respectively). Using similar methods, we will evaluate whether there are 
disparate eff ects of sex, race/ethnicity and other sociodemographic factors on outcome changes and goals -of-care 
preference stability from T2 to T3 and T3 to T4, respectively  
 
9.4.3  ANALYSIS OF THE SECONDARY ENDPOINT(S)  
 
Analysis of secondary endpoints are not dependent on f indings of primary endpoints.  
 
SPI[INVESTIGATOR_645096] s urrogates’ post -bereavement psychological distress : We will use the same approach as 
in the analysis of the primary endpoints to compare anxiety, depression, and post -traumatic distress symptoms in 
SPI[INVESTIGATOR_645097]  9-month (or 
extended) follow -up. 
 
Implementation process outcomes:  Quantitative data on acceptability, fidelity, and costs of SPI[INVESTIGATOR_645098]. SPI[INVESTIGATOR_645099] 75% of responses exceed an average summative score ≥ 3 (of 4) on the acceptability 
measures. Cost estimates will be used to a scertain resources needed to implement or replicate SPI[INVESTIGATOR_645100] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   38 future.92 We will also explore the relationships of these quantitative data with characteristics of settings and 
stakeholders. Transcripts of acceptability interviews will be transferred to ATLAS.ti for analysis. Content analysis 
techniques93 will be used without preconceived categories.94 Open coding will be applied95 and disagreements on 
coding will be resolved by [CONTACT_21128]. We will examine the data for patterns or differences in themes between 
those with acceptability scores >=3 and scores <3 and setting characteristics. This analysis will be facilitated by 
[CONTACT_645171]96 so that what 
contributed to acceptability scores that are po sitive and less than positive may be identified. We will use a similar 
approach, content analysis, to evaluate the sustainability data.  
 
 
9.4.4  SAFETY ANALYSES  
 
Not applicable.  
 
9.4.5  BASELINE DESCRIPTIVE STATISTICS  
 
See 9.4.1 General Approach.  
 
9.4.6  PLANNED INTERIM ANALYSES  
 
Not applicable.  
 
9.4.7  SUB -GROUP ANALYSES  
 
In order to evaluate whether the SPI[INVESTIGATOR_645101], sex, 
race/ethnicity we consider the same generalized mixed effects model in the context of protocol design, 
mentioned in Section 9.4.1.  Our approach is first to consider each factor one at a time.  We will fit the same 
generalized mixed model by [CONTACT_645172] a subject level factor (e .g., race) and its’ interaction with the 
SPI[INVESTIGATOR_61192].  If the interaction is significant the analysis will indicate that SPI[INVESTIGATOR_645102].  We 
will report p -values and importantly, standard errors and confidence intervals by [CONTACT_645173].  
 
For Supplement Aims:  no subgroup analyses will be possible due to the small sample size.  
 
Supplement cohort study:  no subgroup analyses will be possible due to the small sample size  
 
9.4.8  TABULATION OF INDIVIDUAL PARTICIPANT  DATA  
 
Individual participant data will be listed by [CONTACT_8707].  
 
9.4.9  EXPLORATORY ANALYSES  
 
SPI[INVESTIGATOR_645103] -of-life treatment inte nsity : Among patients who die during the initial SPI[INVESTIGATOR_645104] -up, percentages of patients hospi[INVESTIGATOR_057], having ICU admission, having intensive 
procedures and length of hospi[INVESTIGATOR_645105], 
95% CIs, and graphical displays. The exploratory examination of SPI[INVESTIGATOR_61192]’s effectiveness on improving these 
outcomes, we will use the same analytic approach as in the analysis of the primary endpoints  (See 9.4.2) .  
 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   39  
10.1 REGULATORY, ETHICA L, AND STUDY OVERSIGHT CONSIDERATIONS  
 
10.1.1  INFORMED CONSENT PROCESS  
 
[IP_ADDRESS]  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO PARTICIPANTS  
 
Consent forms describing in detail the study intervention , study procedures, and risks are given to the participant  
and written documentation of informed consent is required prior to starting intervention/administering study 
intervention .  The following co nsent materials a re submitted with this protocol.  
• Patient Consent Form -SPI[INVESTIGATOR_61192]  
• Patient Consent Form -Usual Care  
• Surrogate Verbal Consent Form –SPI[INVESTIGATOR_61192]  
• Surrogate Verbal Consent Form – Usual Care  
• Care Provider Verbal Consent Form  
• VERBAL  Consent Addendum – Patient  
• VERBAL  Consent Addendum - Surrogate  
 
For Supplement Aims,  the following consent materials will be used:  
• Patient Verbal Consent  for Screening (cognitive impairment level)  
• Patient Consent Form  
• Surrogate Verbal Consent Form  
 
Supplement cohort study:  
• Verbal Consent Addendum for Cohort – Patient  
• Verbal Consent Addendum for Cohort - Surrogate  
 
 
[IP_ADDRESS]  CONSENT PROCEDURES AND DOCUMENTATION  
 
Participating dialysis centers/clinics will be randomized first (se e the study flow diagram). The care team member 
who has been selected by [CONTACT_645174] a care provider responsible for SPI[INVESTIGATOR_645106] 
(e.g., nurse or social worker) will generate a list of patients each quarter based on the i nclusion criteria . This staff 
member may differ from clinic to clinic depending on who is qualified, comfortable and able to assess each 
potential participant . The medical director of the dialysis unit (and/ or the attending physician as required ) 
approves the list  if required by [CONTACT_645175] .  From this l ist, one of the care provider s will then assess the  
patient’s wi llingness to meet with a recruiter from the research team. The recruiter (e.g., site c oordinator) will 
then approach willing patients during their scheduled dialysis clinic appointment.  
 
Consent forms have been  Institutional Review Board ( IRB)-approved and the participant  will be asked to read and 
review the document.  In a private room, a  verbal explanation will be provided in terms suited to the  patient’s 
comprehension of the purposes, procedures, and potential risks of the study and of their rights as research 
participan ts.  Patient participants  will have the opportunity to carefully review the written consent form (including 
HIPAA authorization from) and ask questions prior to signing.  The patient participant s should have the 
opportunity to discuss the study with their family or surrogates or think about it prior to agreeing to participate. 
The patient participant  will sign the informed consent document prior to any procedures being done specifically 
for the study.  Patient participant s must be informed that participation is voluntary and that they may withdraw 
from the study at any time, without prejudice.  A copy of the informed consent document will be given to the 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   40 participant s for their records. The informed consent process will be conducted and  documented in the source 
document (including the date), and the form signed, before the participan t undergoes any study -specific 
procedures.  The rights and welfare of the participant s will be protected by [CONTACT_645176] . The recruiter will 
then provide the patient participant with a study brochure and encourage him/her to talk to the surrogate 
regarding the study within the next 2 -3 days (to avoid a cold call).  
 
Several days later, the recruiter will telephone the potential surrogate  participant  to assess his/her willingness to 
participate. Following the Surrogate Verbal Consent Form,  a verbal explanation will be provided in terms suited to 
the surrogate’s comprehension of the purposes, procedures, and potential risks of the study and of their rights as 
research participants.  Upon the surrogate’s verbal consent  using the IRB approved sc ript/form , the research staff 
at the Emory Study Coordination Center will schedule  and conduct a baseline data  collection session . All 
surrogates  will provide verbal consent only  with a waiver of written consent and a Surrogate Verbal Consent form 
will be signed by [CONTACT_158592] .  
 
For Supplement Aims:  
Participants will be recruited from the Emory dialysis centers and UVA dialysis centers . First, patients who have 
been diagnosed with an early stage of dementia (mild to moderate) or are suspected of having cognitive 
impairment by a care provider will be referred by [CONTACT_645154]. The medical records of those patients will be 
reviewed to preliminarily determine eligibility by a research staff member. During the patient ’s dialysis treatment 
session at the center, the patient’s care provider will gain permission for the staff member to explain the study. 
With the patient’s permission, the staff member will approach the patient, briefly explain the study, obtain verbal 
consent to conduct the MOCA or SLUMS and UBACC screening. If the patient has met the criteria for both early 
stages of cognitive impairment and decision -making capacity, the research staff member will provide detailed 
study information and confirm his/her sur rogate decision -maker. Written consent will then be obtained from the 
patient. The research staff member will obtain the name [CONTACT_645186] (or confirm with the 
medical record as necessary) and call the surrogate in 2 -3 days to assess t he surrogate’s willingness to participate. 
Verbal consent will be obtained from the surrogate.  
 
Supplement cohort study:  
At the upcoming scheduled monthly check -in call with the participant (in the parent study, a check -in telephone 
call [scripted] is made to each member of the dyad after the 2 -week follow -up call), the research staff member 
will proceed with the procedures for the parent study and then introduce the participant to the supplement 
study, including th e purpose and procedures  and obtain verbal consent. After both members of the dyad have 
consented, the recruiter will schedule two data collection calls (baseline/T3 and 6 months/T4).  
10.1.[ADDRESS_863516] udy is terminated or suspended, the  Principal Investigator ( PI) will promptly inform study 
participants, the Instituti onal Review Board ( IRB), and sponsor and will provide the reason(s) for the termination 
or suspension.  Study participants will be contact[INVESTIGATOR_530], as applicable, and be informed of changes to study 
appointment schedule.  
  
Circumstances that may warrant termination or suspension inclu de, but are not limited to:  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   41 • Determination of unexpected, significant, or unacceptable risk to participants  
• Insufficient compliance to protocol requirements  
 
Study may resume once concerns about safety, protocol compliance, and data quality are addressed , and satisfy 
the sponsor and IRB.  
 
10.1.[ADDRESS_863517] ( IRB), regulatory agencies  may inspect all documents and records required to be maintained by [CONTACT_1275], including but not limited to, medical records (office, clinic ), for the participant s in this s tudy. The 
clinical study site will permit access to such records.  
 
The study participant’s contact [CONTACT_645177]. At the end of the study, all paper records will continue to b e kept in a secure location for as long 
a period as dictated by [CONTACT_54232], Institutional policies, or sponsor requirements . 
 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be directly 
entered into  and stored in REDCap  study database . Individual participants and their research data will be 
identified by a unique study identification number.  All information collected during the study will be secured and 
password protected. At the end of t he study, all study databases will be de -identified and archived at the Emory 
Study Coordination Center . 
 
10.1.[ADDRESS_863518] NE, Atlanta, GA [ZIP_CODE]  
[PHONE_13400]  
[EMAIL_12288]  Project Director  
Mary Laszlo  
Project Manager  
Emory School of Nursing  
[PHONE_13401]  
[EMAIL_12289]  
Study Site  Site PI  [INVESTIGATOR_645107]-Kyung Song  
 Mary Laszlo  
Project Manager  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   42 University of North Carolina at Chapel 
Hill Abhijit Kshirsagar, MD, MPH  
Associate [CONTACT_645190], UNC Dialysis 
Care  
UNC Kidney Center  
CB 7155 Burnett -Wormack  
Chapel Hill, NC [ZIP_CODE]  
[PHONE_13402]  
[EMAIL_12290]   
University of Pi[INVESTIGATOR_645108], MD, MPH  
Assistant Professor  
UPMC Presby[CONTACT_194840] [ADDRESS_863519]  
Suite C11 00, Rm C1103  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
[PHONE_13403]  
[EMAIL_12291]   
University of New Mexico  Mark Unruh, MD , MS  
Professor and Chair  
UNM, Internal Medicine  
DoIM MSC10 -5550  
1 University of New Mexico  
Albuquerque, NM   [ZIP_CODE]  
[PHONE_13404]  
[EMAIL_12292]   
University of Virginia  Maureen Metzger, RN, PhD  
Associate [CONTACT_40758] of Virginia School of Nursing  
[PO_BOX]  
5038 McLeod Hall  
Charlottesville, VA [ZIP_CODE] -0782  
[PHONE_13405]  
[EMAIL_12293]  
 
Emaad Abdel -Rahman, MD PhD, FASN  
(Co-Inves tigator)  
[CONTACT_645191]/Nephrology  
Division of  Nephrology  
UVA  
[PO_BOX]  
Charlottesville, VA [ZIP_CODE]  
[PHONE_13406]  
[EMAIL_12294]   
Other study co -investigators:  
Laura Plantinga, PhD  
Assistant [CONTACT_645192] of Medicine  
Renal Division  
[EMAIL_12295]  
 Janice I.P. Lea, MD, MSc  
Professor of   Medicine  
Chief Medical Director Emory Dialysis  
Clinical Specialist in Hypertension  
Emory University School of Medicine  
Renal Division  
[ADDRESS_863520]. 7th floor, MOT  
Atlanta, GA [ZIP_CODE]  
[PHONE_13407]  
[EMAIL_3426]  Amita Manatunga, PhD  
[CONTACT_124106] of Public Health  
Emory University  
[ADDRESS_863521] NE  
Atlanta, GA [ZIP_CODE]  
[PHONE_13408]  
[EMAIL_12296]  
Sandra Ward, PhD, RN , [CONTACT_645193] of Wisconsin -Madison  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   43 [PHONE_13409]  
[EMAIL_12297]  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   44 Study organization and coordination  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For Supplement Aims:  
Principal Investigator  
[INVESTIGATOR_644921]-Kyung Song, PhD, RN  
[CONTACT_14694], School of 
Nursing  
[ADDRESS_863522] NE, Atlanta, 
GA [ZIP_CODE]  
[PHONE_13400]  
[EMAIL_12288]  
 Coordinator  
Taylor Adkins, M PH 
Research Coordinator  
Emory University  
[PHONE_13410]  
[EMAIL_12298]  
 Co-
Investigator/Statistician  
Sudeshna Paul, PhD  
Assistant [CONTACT_14694], School of 
Nursing  
[EMAIL_12299]  
 Co-Investigator  
Linda Turbevill -Trujillo, MSN, 
ANP  
Emory Healthcare  
linda.turberville -
[EMAIL_12300]  
Co-Investigator  
Drenna Waldrop -Valverde, 
PhD 
[CONTACT_14694], School of 
Nursing  
drenna.waldrop -
[EMAIL_12301]  
 Co-Investigator  
Janice I.P. Lea, MD, MSc  
Professor of  Medicine  
Chief Medical Director 
Emory Dialysis  
Clinical Specialist in 
Hypertension  
Emory University School of 
Medicine  
Renal Division  
[ADDRESS_863523]. 7th floor, 
MOT  
Atlanta, GA [ZIP_CODE]  
[PHONE_13407]  
[EMAIL_3426]    

SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   45  
Supplement cohort study:  
 
 
 
10.1.[ADDRESS_863524] ( DSMB ) composed of [ADDRESS_863525] (see signed disclosure forms) .   
 
The DSMB will meet bi -annually to evaluate the study progress, including assessment of data quality, timeliness, 
participant recruitment, rates of eligibility and ineligibility across study clinics and sites/states, acc rual and 
retention, participant risk versus benefit, performance of trial sites, patient deaths, and any adverse events or 
care providers’ concerns that can affect study outcome. Consistent with prior end -of-life communication 
interventions, including our prior trials, we do not expect that the intervention will alter mortality rates. 
Nonetheless, this will be one of the measures monitored by [CONTACT_4318]. The DSMB will compare recruitment rate 
and sample characteristics to assumptions used for power calculatio ns. The DSMB will monitor the design factor, 
intra -cluster correlation coefficient, to assess whether the study will have expected power. Formal interim 
analyses are not planned for several reasons: (a) the SPI[INVESTIGATOR_645109], (b) risks a ssociated with 
SPI[INVESTIGATOR_645110], (c) the control condition is usual care, not a placebo, and (d) the proposed study also 
aims to gather implementation data, including sustainability, that are critical for widespread implementation. 
Finally, the DSMB  will not monitor fidelity/adherence data and make recommendations for ways to improve 
adherence because of the pragmatic nature of the proposed trial (i.e., seeking real world answers).  The DMSB will 
operate under the rules of an approved charter that wil l be written and reviewed at the organizational meeting of 
the DSMB.  
 
See DSMB Charter.  
 
For Supplement Aims:  
Although the proposed study involves minimal risk, we will implement a data and safety monitoring plan at 
multiple levels to ensure the safety of  participants and the validity and integrity of the data:  
 
(1) The PI/[CONTACT_461042] will convene weekly meetings with staff to review progress, subject accrual, and any 
anticipated and unanticipated problems. The weekly progress information will be aggregated for r eports 
and presented at bi -monthly or monthly all investigators meetings.  
(2) The PI/[CONTACT_461042] will convene a videoconference with the study investigators monthly. At these meetings 
the investigators will assess study performance related to subject recruitment,  review the quality of the 
data, and discuss any adverse events. The investigators will determine any need for re -training of study 
staff.  Principal Investigator  
[INVESTIGATOR_644921]-Kyung Song, PhD, RN  
[CONTACT_14694], School of 
Nursing  
[ADDRESS_863526] NE, Atlanta, 
GA [ZIP_CODE]  
[PHONE_13400]  
[EMAIL_12288]  
 Coordinator  
Mary C Laszlo  
Research Project Manager  
Emory University, School of 
Nursing  
[PHONE_13401]  
[EMAIL_12302]  
 Co-
Investigator/Statistician  
Sudeshna Paul, PhD  
Assistant [CONTACT_14694], School of 
Nursing  
[EMAIL_12299]  
 Co-Investigator  
Sandra Ward, PhD, RN , 
[CONTACT_645193] of Wisconsin -
Madison  
[PHONE_13409]  
[EMAIL_12297]  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   46 (3) We will set up a Data and Safety Monitoring Committee (DSMC) responsible for reviewing trial data on 
an ongoing basis  to ensure the safety of study participants and validity and integrity of the study data. 
The DSMC will include [ADDRESS_863527] in SPI[INVESTIGATOR_645111] 
(to-be-named; e.g., investigators in the field and academic i nstitutions, and biostatistician).  
 
The DSMC will meet with the PI [INVESTIGATOR_645112], 
including informed consent procedures, participant recruitment, rates of eligibility and ineligibility, 
assessment of da ta quality, timeliness, and retention, participant risk versus benefit, breaches in 
confidentiality, patient deaths, and any adverse events or care providers’ concerns that can affect the 
protection of human subjects and study outcome.  
 
The first meeting will occur at the beginning of the trial. At this meeting, the committee will review the 
study protocols, including consenting procedures, recruitment and retention procedures for practicality 
and protection of human subjects and make recommendatio ns as needed. At the subsequent annual 
meetings, the DSMC will review:  
a. Timeliness in meeting the goals for recruitment and retention  
b. Adherence to the study protocols  
c. Adherence to the intervention protocol  
d. Data related to adverse events  
e. Quality, completenes s, and timeliness of the data collected  
f. Factors that could affect the outcome or compromise data or confidentiality  
g. Other factors outside the study, such as therapeutic developments, agency related to policies 
that could impact the safety of participants o r the ethical conduct of the study  
 
In general, recommendations the DSMC may make include:  
a. Continue the study without change  
b. Modifications to the study protocol  
c. Suspension or early termination  
d. Alternative approaches to consider (e.g., if there is a failur e to accrue participants as planned)  
 
The information about adverse events that occur during the study will be sent to the DSMC chairperson, who will 
distribute it to the other members of the committee. The relatedness of the event to the study would be pr ovided 
at the time of presentation of the information. In addition, the Emory University IRB and the NIH Program Officer 
will be notified within one week of the event by [CONTACT_978].  
 
10.1.[ADDRESS_863528] of the trial is in 
compliance with the currently approved protocol/amendment(s), with International Conference on 
Harmonisation Good Clinical Practice ( ICH GCP), and with applicable regulatory requirement(s).  
 
All study data will be directly entered into REDCap. The data entry forms in REDCap will be set up such that out -of-
range values are not accepted , which will minimize data entry error .  Although HADS (anxiety and dep ression 
symptom scales) and PTSS -10 (post -traumatic distress symptom screening) are not diagnostic tools, when  a 
surrogate’s HADS score is abnormal ( Depression score ≥15 ), the REDCap data entry form will flag the research 
staff to  notify the surrogate that  the local research staff  member may confer with the Site PI [INVESTIGATOR_645113] a local mental health if necessary.  
 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   47 • The PI [INVESTIGATOR_645114]. A random 
review of 10% primary endpoint data and secondary endpoint data (HADS and PTSS -10) will be 
performed. A monitoring report will be generated at completion of review and will be shared with the 
study site teams.   
• Independent audits  will not be conducted as this trial does not collect clinical data after baseline (as 
descriptors).  
 
10.1.[ADDRESS_863529] Operating Procedures (SOPs). These SOPs will be accessible via REDCa p.  
 
Data collectors/recruiters will attend a competency based, one -day training session that the PI [INVESTIGATOR_645115]. Following a demonstration by [CONTACT_978] [INVESTIGATOR_645116], the recruiters will be expected to perform three satisfactory practice recruitment 
sessions before actual performance. The final practice sessions will be audio - or video -recorded and reviewed for 
adherence to the protocol. After demonstrating satisfactory per formance of consenting sessions, the recruiters 
will be authorized to recruit and enroll participants.  
 
Training for data collection will include scripted data collection techniques with special attention to assessing 
participant fatigue or discomfort dur ing the data collection session. Data collectors will conduct a series of three 
practice baseline and follow -up data collections using volunteers. After demonstrating satisfactory performance 
on data collection, they will be authorized to perform data coll ection activities  with enrolled participants. They 
will also need to demonstrate completeness of data collection activities using REDCap.  
 
Each study site will perform internal quality management of study conduct, data collection, documentation and 
comple tion.  In general the following strategies will be employed:  
• Use of data collection and data entry SOP  
• Before ending the data collection session, review the data entry form in REDCap for any missing data  
• Each data collector signs his/her work  
• Audit research staff members’ performance (e.g., consenting and data collection ) Biannually . 
 
We will also employ systematic checking of data quality : The project director at the Emory Study Coordination 
Center will run quality control checks on the database  quarterly ; any missing data or data anomalies will be 
reported to the PI [INVESTIGATOR_645117](s) for clarification/resolution.  
 
The PI/[CONTACT_461042] will convene weekly meetings with staff to review progress, subject accrual, and any 
unanticipated problem s at the Emory site. Site PIs will do the same at their respective study sites. The weekly 
progress information will be aggregated for reports and presented at bi -monthly or monthly all study sites 
meetings.  
 
To ensure compliance with the monitoring plan a nd reporting requirements across study sites, the PI/[CONTACT_461042] at 
the Study Coordination Center  will convene a videoconference (using Adobe Connect or Zoom ) with the study 
investigators, project director, SPI[INVESTIGATOR_645030], and site coordinators monthly . At these meetings the investigators 
will assess study performance related to subject recruitment across the study sites (at least 1 dyad per month in a 
small c luster and 3 dyads in a larger cluster), review the quality of the data, and discuss any adverse events.  
 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.[ADDRESS_863530]  KEEPI[INVESTIGATOR_1645]   
 
[IP_ADDRESS]  DATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
 
The School of Nursing at Emory University, the Emory site, will be the Study Coordination Center  and will maintain 
close contact [CONTACT_645178]. All study sites will use a common 
study web -portal using the Research Electronic Data Capture (REDCap) created and manage d in Emory SON. Each 
site will create and update study participants’ data through REDCap. During data entry, automated checks will be 
performed that will immediately flag problematic data (e.g., missing, out of range, inconsistent), allowing for the 
sites to address any discrepant data promptly thus increasing data quality. Data entered into the web -based form 
are immediately stored in a study database and tracked through a journaling process where they are accessible 
for review by [CONTACT_3476]. Social Se curity numbers are entered directly into REDCap and not listed on paper 
forms. Suspi[INVESTIGATOR_537049] a query management system, and automated alerts provided to 
the sites.  A complete audit trail is stored for each database modification.  Any discrepant data identified through 
analytic manipulations will be communicated to the sites. Once all queries have been resolved and the database 
has been deemed “clean”, it will be officially locked.  All permissions to make changes (append, delete, modi fy or 
update) to the database by [CONTACT_645179].  
 
Record keepi[INVESTIGATOR_6926] d ata collection  (recruitment data, patient medical record review at enrollment, clinic -
contextual data, SPI[INVESTIGATOR_645118])  are the responsibilit ies of the research  staff at the site under the 
supervision of the site investigator . The investigator is responsible for ensuring the accuracy, completeness, 
legibility  (if hardcopi[INVESTIGATOR_645119]) , and timeliness of the data reported . 
 
[IP_ADDRESS]  STUDY RECORDS RETENTION  
 
All study’s written records will be stored in a locked cabinet for [ADDRESS_863531] and IRB approval (Resource and Data Sharing Plans).  
 
10.1.10  PROTOCOL DEVIATIONS  
 
A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on 
Harmonis ation Good Clinical Practice ( ICH GCP) , or Manual of Procedures ( MOP) requirements. The 
noncompliance may be either on the part of the participant , the investigator, or the study site staff. As a result of 
deviations, corrective actions are to be developed by [CONTACT_3483].  
 
It is the responsibility of the site investigator to use continuous vigilance to identify and report devi ations within 7 
working days of identification of the protocol deviation.   See Protocol Deviation/Violation Report Form and the 
related SOP.   All deviations will be addressed in study source documents, reported to the Study Coordination 
Center .  The site investigator  is responsible for knowing and adhering to the  reviewing IRB requirements.  
 
10.1.11  PUBLICATION AND DATA SHARING POLICY  
 
This study will  be conducted in accordance with the following  publication and data sharing  policies and 
regulations:  
National Institutes of Health ( NIH) Public Access Policy , which ensures that the public has access to the published 
results of NIH funded research. It requires scientists to submit final peer -reviewed journal manuscripts that ari se 
from NIH funds to the digital archive PubMed Central  upon acceptance for publication.  
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -Funded Clinical 
Trial Information and the Clinical Trials Registration and Results Information Submission r ule. As such,  this trial has 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   49 been  registered at ClinicalTrials.gov , and results information  from this  trial will be submitted to ClinicalTrials.gov.  
In addition, every attempt will be made to publish results in peer -reviewed journals.   
 
Authorship determination:  Authorship confers credit and has important academic, social, and financial 
implications. Authorship  also implies responsibility and accountability for published work. We will follow the 
recommendations by [CONTACT_4717] (ICMJE) to determine authorship (vs. 
non-author contributors).  http://www.icmje.org/recommendations/browse/roles -and-responsibilities/defining -
the-role-of-authors -and-contributors.html    
Authorship will be based on the following 4 criteria:  
1. Substantial contributions to the conception or design of the work or the acquisition, analysis, or 
interpretation of data for the work; AND  
2. Drafting the work or revision it critically for import ant intellectual content  (simply participating in writing 
or technical editing of the manuscript is insufficient for authorship); AND  
3. Final approval of the version to be published; AND  
4. Agreement to be accountable for all aspects of the work in ensuring tha t questions related to the 
accuracy or integrity of any part of the work are appropriately investigated and resolved.  
Those who do not meet all 4 of the above criteria will be acknowledged as non -author contributors.  
 
Data sharing:  
We will make the fina l data from the study, including a codebook, available to researchers after acceptance for 
publication of the main findings from the final dataset. The final data will be a complete and cleaned data set free 
of identifiers. We will make the research data a vailable to users with a data -sharing agreement that includes: (1) a 
commitment to using the data only for research purposes, (2) a commitment to securing the data using 
appropriate computer technology, (3) a commitment to destroying the data after analyse s are completed and not 
redistributing to third parties, and (4) IRB approval and clear research questions. Data request and sharing 
procedures, data request forms, and a data -sharing agreement will be accessible through the website of Center 
for Nursing E xcellence in Palliative Care, Nell Hodgson Woodruff School of Nursing. The requester will be able to 
download final dataset and codebook. Also, care providers or administrators who wish to use the SPI[INVESTIGATOR_645120] a request through the Center’s website and will be able to 
download the SPI[INVESTIGATOR_645121].  
 
10.1.[ADDRESS_863532].  
 
10.2 PROTOCOL  AMENDMENT  HISTORY  
 
Version  Date  Description of Change  Brief Rationale  
1 29-June -2017  Original draft   
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   50 2 25-
September -
2017  From: waiver of written consent for 
surrogates from the control clinics  
To: waiver of written consent for all 
surrogates  
 
From: audio -recording surrogate verbal 
consent  
To: no audio -recording surrogate verbal 
consent  To make the consent process 
consistent between the 
intervention and control groups 
and the intervention’s safe ty has 
been proven, involving no greater 
than minimal risk. This change will 
also reduce the risk of breach of 
confidentiality by [CONTACT_645180] 1 
copy signed by [CONTACT_88060].  
From: the SPI[INVESTIGATOR_645122]: Procedure for dialysis clinic 
identification of potential 
participants with “no” to SQ 
question will be determined by [CONTACT_645181]. The 
culture and workflow of the 
dialysis clinic should be respected.  
 
For PD patients who have to travel far to 
visit the clinic, SPI[INVESTIGATOR_645123] 4 
weeks after Session I.  To coincide with the next monthly 
clinic visit and thus reduce the 
travel burden.  
 
Severe depression symptom scores 
(HADS -Depression ≥ 15) score given 
procedure for referral.  
Add response to suicidal ideation  
With a high HADS -depression score, the 
surrogate should be informed and 
encouraged to consider talking to the 
primary care provider.  
If suicidal ideation is  expressed, site 
coordinator is notified and he/she will 
address with Site PI.  Subject safety  
3 25 January - 
2018  Remove: copy of verbal consent will be 
mailed.  
Changed name [CONTACT_645189]. of Pi[INVESTIGATOR_645124].  
For information purposes only.  
4 31 July 2018  Addition of DCI  and Emory Decatur to 
Emory University Sites  In order to meet recruitment goals  
5 
 4 December 
2018  Deletion of Surprise Question inclusion 
criterion and addition of 
teleconferencing f or SPI[INVESTIGATOR_645125].  
 Delete: Surprise Question - “would I be 
surprised if the patient died in the next 
year?”  
 
 
 
 
 
 
 
 Renal community has been 
promoting timely advance care 
planning for every patient on 
dialysis regardless of their current 
health condition because of their 
high comorbidity an d 
unpredictable prognosis. Because 
the SPI[INVESTIGATOR_645126], the investigators have 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   51  
 
 
 
 
 
 
 
Allow for teleconferencing for 
Intervention delivery (Using Zoom, LITS 
approved platform)  
 decided to broaden the inclusion 
criteria by [CONTACT_645182]. This change will also help 
ensure t he study meets the target 
sample size within the proposed 
timeline.  
 
Chosen Surrogates may not live 
locally and this would allow their 
participation in a secure and 
private setting and alleviate 
transportation and schedule 
demands.  
 
 
6 21 January 
2019  Add: University of Virginia as study site  Additional University site added to 
increase recruitment to meet study 
milestones and targets.  
7 27 February 
2019  1.1 Synopsis  
4.1 Overall study design  
9.4.3 analysis of secondary endpoint(s)  
9.4.9 Exploratory analysis  
[IP_ADDRESS] Consent/Assent  
 
Study Duration: Patients & Surrogates 
participation duration of [ADDRESS_863533] 
data collection; we will request an 
extension of [ADDRESS_863534] had  very few patient 
deaths (less than 4% of recruited 
population) and we run the risk of 
not meeting secondary aims unless 
we can extend the follow up 
period. This will be done by 
[CONTACT_645183] [ADDRESS_863535] 
2019  Note: Below revisions are all related to 
the supplement study, and the parent 
study is not affected.  
 3 Aims, endpoint, phases, Emory only 
sites, duration ~ [ADDRESS_863536] plus dementia – use of MoCA, 
SLUMS and UBACC  
Same; patients previously excluded will 
have opportunity under supplement  
Transportation support offered  
 
Single session due to patients limited 
short -term memory  
Addition of MoCA and SLUMS  We request approval fo r a 
modification to the current 
protocol to evaluate the effects of 
SPI[INVESTIGATOR_645127]. This additional 
evaluation of SPI[INVESTIGATOR_61192] a dded to the 
current protocol has been funded 
by [CONTACT_18121]. Dialysis patients will 
continue to be assessed for their 
eligibility for the parent study. If 
they meet the inclusion criteria for 
the current parent study, they will 
move along with the existing 
pathway. If they are determined to 
be ineligible due to cognitive 
impairment, those patients may be 
qualified for this sub -study. Having 
these two pathways, patients who 
are excluded from the parent study 
but still able to consent for study 
participation and able to express 
their wishes will have an 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   52  
Randomization by [CONTACT_645184]; SPI[INVESTIGATOR_644964].  
 
Addition: Audio recording of sessions 
and sequent qualitative analysis  
[ADDRESS_863537] -death HADS for surrogate, 
medical records review at 6m or death  
 
AIMS 1 & 2, sample size = 30  
 
AIM 1: Preparedness and Care decisions; 
AIM 2: Srgt post -bereavement distress: 
AIM3: Decision making capacity  
 
Pt written consent, Srgt verbal consent 
and Screening HIPAA. Limit to Emory 
Sites. Use of MoCA and SLUMS  
 
Add: [CONTACT_115280], biostatisitian, Linda 
Turberville -Trujillo ANP, and Drenna 
Waldrop -Valverde, PhD  opportunity to participate. This 
sub-study will involve Emory 
dialysis centers only. If patients are 
eligible for the pathway of the sub -
study, they will be randomized 
either to receive usual care only or 
to receiv e SPI[INVESTIGATOR_645128]. We 
have brought in additional 
investigators who have expertise in 
neuroscience and cognition.  
 
9 July 29, 2020  Changes in 5.5. Strategies for 
recruitment and retention and 6.0 Study 
intervention   
Supplement study procedures to be 
done remotely/via phone  
During the pandemic, SPI[INVESTIGATOR_645129].  To avoid or minimize in -person 
contacts.  
  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   53 5.5. Strategies for 
recruitment and 
retention  
 
6.0 Study 
intervention  July 29, 
2020  Supplement study procedures to be done 
remotely/via phone  
 
 
During the pandemic, SPI[INVESTIGATOR_645130].  
 To minimize in -person contacts  
10 
 
1.1 Synopsis  
2.1 Study rationale  
2.2 Study 
background  
4.1 Overall study 
design  
4.2 Scientific 
rationale for study 
design  
4.4 End of study 
definition  
5.1 Inclusion 
criteria  
5.5 Strategies for 
recruitment and 
retention  
8.1 Outcome 
assessments  
9.1 Statistical 
hypotheses  
9.2 Sample size 
determination  
9.4 Statistical 
analyses  
10.1 Regulatory, 
ethical, and study 
oversight 
considerations  
 8/12/[ADDRESS_863538] 
of the pandemic on the stability of 
end-of-life care preferences and on 
our key outcomes (dyad 
congruence on goals of care, 
patient decisional conflict, and 
surrogate decision -making 
confidence).  
 
11 10-
.22.2020  5.1 Inclusion Criteria: *Changes are related to 
supplemental aim (SPI[INVESTIGATOR_645131]),  and do not affect the parent study.  
 Supplement study: Adjusting the 
MoCA  and SLUMS criterion to 
meet target sample size .  
 
12 
 1/8/2021  5.5 Recruitment : Care Providers recruitment and 
consent procedures  
 
 Recruitment involves email 
contacts and phone calls.  
Current informed consent for Care 
Providers is not changing.  
 
 
11 REFERENCES  
1. [LOCATION_002] Renal Data System. 2015 USRDS annual data report: Epi[INVESTIGATOR_645132]. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive 
and Kidney Diseases, 2015.  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   54 2. Renal Physicians Association. Shared decision -making in the appropriate initiation of and withdrawal from 
dialysis: Clinical practice guideline. 2nd ed. Rockvi lle, MD: Renal Physicians Association, 2010.  
3. Kolarik RC, Arnold RM, Fischer GS, Tulsky JA. Objectives for advance care planning. J Palliat Med 
2002;5:697 -704.  
4. Tulsky JA. Beyond advance directives: importance of communication skills at the end of life . JAMA 
2005;294:359 -65. 
5. Institute of Medicine. Dying in America: Improving quality and honoring individual preferences near the 
end of life. Washington, D.C.: The National Academy of Sciences, 2014.  
6. Davison SN. Facilitating advance care planning for patients with end -stage renal disease: The patient 
perspectives. Clinical Journal of the Amedican Society of Nephrology 2006;1:1023 -1028.  
7. Goff SL, Eneanya ND, Feinberg R, Germain MJ, Marr L, Berzoff J, Cohen LM, Unruh M. Advance Care 
Planning: A Qualita tive Study of Dialysis Patients and Families. Clin J Am Soc Nephrol 2015;10:[ADDRESS_863539] ME, McCullough LB. Voices of African American, Caucasian, and Hispanic 
surrogates on the burdens of end -of-life decision making. Journal of Gen eral Internal Medicine 
2008;23:267 -74. 
9. Cherlin E, Fried T, Prigerson HG, Schulman -Green D, Johnson -Hurzeler R, Bradley EH. Communication 
between physicians and family caregivers about care at the end of life: when do discussions occur and 
what is said? J Palliat Med 2005;8:[ADDRESS_863540] deaths. 
American Journal of Kidney Diseases 2005;45:154 -61. 
11. Cohen LM, Poppel DM, Cohn GM, Reiter GS. A very good death: measuring qua lity of dying in end -stage 
renal disease. J Palliat Med 2001;4:167 -72. 
12. Hebert RS, Dang Q, Schulz R. Preparedness for the death of a loved one and mental health in bereaved 
caregivers of patients with dementia: findings from the REACH study. J Palliat M ed 2006;9:683 -93. 
13. Hebert RS, Schulz R, Copeland VC, Arnold RM. Preparing Family Caregivers for Death and Bereavement. 
Insights from Caregivers of Terminally Ill Patients. Journal of Pain and Symptom Management 2009;37:3 -
12. 
14. Wendler D, Rid A. System atic review: the effect on surrogates of making treatment decisions for others. 
Annals of Internal Medicine 2011;154:[ADDRESS_863541] S. A representational approach to patient education. J Nurs Scholarsh 2001;33:[ADDRESS_863542] SE, Song MK, Heidrich SM, Gunnarsdottir S, Phillips CM. An update on the 
representational approach to patient education. J Nurs Scholarsh 2007;39:[ADDRESS_863543] SE, Hammes BJ. A randomized, controlled trial to improve 
advance care planning among patients undergoing cardiac surgery. Medical Care 2005;43:[ADDRESS_863544] SE, Happ MB, Pi[INVESTIGATOR_124412] B, Donovan HS, Shields AM, Connolly MC. Randomized controlled 
trial of SPI[INVESTIGATOR_61192]: An effective approach to preparing African American dialysis patients and families for end -
of-life. Research in Nursing & Health 2009;32:260 -273.  
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.[ADDRESS_863545] SE. Effects of an intervention to 
improve communication about end -of-life care among African Americans with chronic kidney disease. 
Applied Nursing Research 2010;23:[ADDRESS_863546] SE, Fine JP, Hanson LC, Lin FC, Hladik GA, Hamilton JB, Bridgman JC. Advance care 
planning and end -of-life decision making in dialysis: A randomi zed controlled trial targeting patients and 
their surrogates. American Journal of Kidney Diseases 2015;66:813 -22. 
21. Goodman DC, Esty AR, Fisher ES, Chaning CH. Trends and variation in end -of-life care for Medicare 
beneficiaries with severe chronic illnes s: A report of the Darthmouth Atlas Project. Lebanon, NH: 
Dartmouth Institute for Health Policy & Clinical Practice, 2011.  
22. Wong SP, Kreuter W, O'Hare AM. Treatment intensity at the end of life in older adults receiving long -term 
dialysis. Archives of I nternal Medicine 2012;172:661 -3; discussion 663 -4. 
23. Cohen LM, Germain MJ, Poppel DM. Practical considerations in dialysis withdrawal: "to have that option is 
a blessing". JAMA 2003;289:2113 -9. 
24. Holley JL, Hines SC, Glover JJ, Babrow AS, Badzek LA, Mo ss AH. Failure of advance care planning to elicit 
patients' preferences for withdrawal from dialysis. American Journal of Kidney Diseases 1999;33:688 -93. 
25. Calvin AO. Haemodialysis patients and end -of-life decisions: a theory of personal preservation. Jo urnal of 
Advanced Nursing 2004;46:[ADDRESS_863547] SD, Carmody SS, Bruns FJ, Rotondi AJ, Cohen LM, Zeidel ML, Arnold RM. Symptom burden, 
quality of life, advance care planning and the potential value of palliative care in severely ill haemodialysis 
patients. Nephrology, Dialysis, Transplantation 2003;18:1345 -52. 
27. Davison SN. End -of-life care preferences and needs: perceptions of patients with chronic kidney disease. 
Clin J Am Soc Nephrol 2010;5:195 -204.  
28. Singer PA, Thiel EC, Naylor CD, Richardson RM, Llewellyn -Thomas H, Goldstein M, Saiphoo C, Uldall PR, 
Kim D, Mendelssohn DC. Life -sustaining treatment preferences of hemodialysis patients: implications for 
advance directives. Journal of the American Society of Nephrology 1995;6:[ADDRESS_863548] SE, Hanson LC, Metzger M, Kim S. Determining consistency of surrogate decisions and 
end-of-life care received with patient goals -of-care preferences. Journal of Palliative Medicine 
2016;19:610 -6. 
30. Pruchno RA, Lemay EP, Jr., Feild L, Lev insky NG. Predictors of patient treatment preferences and spouse 
substituted judgments: the case of dialysis continuation. Medical Decision Making 2006;26:112 -21. 
31. Pruchno RA, Lemay EP, Jr., Feild L, Levinsky NG. Spouse as health care proxy for dialysis  patients: whose 
preferences matter? Gerontologist 2005;45:812 -9. 
32. Houts RM, Smucker WD, Jacobson JA, Ditto PH, Danks JH. Predicting elderly outpatients' life -sustaining 
treatment preferences over time: The majority rules. Medical Decision Making 2002;2 2:39 -52. 
33. Sulmasy DP, Haller K, Terry PB. More talk, less paper: Predicting the accuracy of substituted judgments. 
American Journal of Medicine 1994;96:[ADDRESS_863549] SE, Lin FC. End -of-life decision -making confidence in surrogates of African -American 
dialysis patients is overly optimistic. J Palliat Med 2012;15:412 -7. 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   56 35. Badger JM. Factors That Enable or Complicate End -of-Life Transitions in Critical Care. American Journal of 
Critical Care 2005;14:513 -21. 
36. Boyle DK, Miller PA, Forbes -Thomp son SA. Communication and end -of-life care in the intensive care unit: 
patient, family, and clinician outcomes. Critical Care Nursing Quarterly 2005;28:302 -16. 
37. Swigart V, Lidz C, Butterworth V, Arnold R. Letting go: family willingness to forgo life sup port. Heart and 
Lung 1996;25:483 -94. 
38. Hardin SB, Yusufaly YA. Difficult end -of-life treatment decisions: do other factors trump advance 
directives? Archives of Internal Medicine 2004;164:1531 -3. 
39. Abbott KH, Sago JG, Breen CM, Abernethy AP, Tulsky JA.  Families looking back: one year after discussion 
of withdrawal or withholding of life -sustaining support. Critical Care Medicine 2001;29:[ADDRESS_863550] -traumatic stress symptoms in family members of intensive care unit patients. American Journal of 
Respi[INVESTIGATOR_50165] 2005;171:987 -94. 
41. Curtis JR, Engelberg RA, Wenrich MD, Shannon SE, Treece PD, Rubenfeld GD. Missed Opportunities during 
Family Conferences about End -of-Life Care in the Intensive Care Unit. American Journal of Respi[INVESTIGATOR_216869] 2005;171:844 -9. 
42. Siegel MD, Hayes E, Vanderwerker LC, Loseth DB, Prigerson HG. Psychiatric illness in the next of kin of 
patients who die in the intensive ca re unit. Critical Care Medicine 2008;36:1722 -8. 
43. Tilden VP, Tolle SW, Nelson CA, Fields J. Family decision -making to withdraw life -sustaining treatments 
from hospi[INVESTIGATOR_9643]. Nursing Research 2001;50:105 -15. 
44. Baggs JG, Schmitt MH. End -of-life d ecisions in adult intensive care: current research base 158 and 
directions for the future. Nursing Outlook 2000;48:158 -64. 
45. Hansen L, Archbold PG, Stewart BJ. Role strain and ease in decision -making to withdraw or withhold life 
support for elderly relat ives. J Nurs Scholarsh 2004;36:[ADDRESS_863551] of 
physicians' behaviors on the family. Archives of Internal Medicine 1995;155:633 -8. 
47. Jacob DA. Family members' expe riences with decision making for incompetent patients in the ICU: a 
qualitative study. American Journal of Critical Care 1998;7:30 -6. 
48. Jeffers BR. The surrogate's experience during treatment decision -making. Medsurg Nursing 1998;7:357 -
63. 
49. Shiozaki M , Hirai K, Dohke R, Morita T, Miyashita M, Sato K, Tsuneto S, Shima Y, Uchitomi Y. Measuring 
the regret of bereaved family members regarding the decision to admit cancer patients to palliative care 
units. Psycho -Oncology 2008;17:926 -31. 
50. Wright AA, Zhan g B, Ray A, Mack JW, Trice E, Balboni T, Mitchell SL, Jackson VA, Block SD, Maciejewski PK, 
Prigerson HG. Associations between end -of-life discussions, patient mental health, medical care near 
death, and caregiver bereavement adjustment. JAMA 2008;300:1665 -73. 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   57 51. Centers for Medicare and Medicaid Services. Medicare and Medicaid Programs; Conditions for Coverage 
for End -Stage Renal Disease Facilities; Final Rule. In: Services DoHaH, editor, 2008.  
52. Centers for Medicare & Medicaid Services. 42 CFR Parts 40 5, 410. 411, 414, 425, and 495 [CMS -1631 -FC] 
Medicare Program; Revisions to Payment Polocies under the Physician Fee Sschedule and Other Revisions 
to Part B for CY 2016. 2015.  
53. Fagerlin A, Schneider CE. Enough. The failure of the living will. Hastings C enter Report 2004;34:30 -42. 
54. Leventhal H, Nerenz D, Steele DS. Illness representations and copi[INVESTIGATOR_645133]. In: Baum A, 
Singer JE, editors. Handbook of psychology and health. [LOCATION_001]: Erlbaum, 1984:221 -252.  
55. Posner G, Strike K, Hewson P, Gertzog W. Accommodation of a scientific conception: Toward a theory of 
conceptual change. Science Education 1982;66:211 -227.  
56. Kleinman A, Eisenberg L, Good B. Culture, illness, and care: clinical lessons from anthropologic and cross -
cultural research. Annals of Internal Medicine 1978;88:251 -8. 
57. Kleinman A, Mendelsohn E. Systems of medical knowledge: a comparative approach. Journal of Medicine 
and Philosophy 1978;3:314 -30. 
58. Hewson M. Patient education through teaching for conceptual chang e. Journal of General Internal 
Medicine 1993;8:[ADDRESS_863552] in conceptual change and the design of instruction. 
Instructional Science 1984;13:[ADDRESS_863553] SE. Making visible a theory -guided advance care planning intervention. J Nurs Scholarsh 
2015;47:[ADDRESS_863554] of an advance care planning intervention evaluated by 
[CONTACT_645185] -makers of dialysis patients. Palliative  Medicine 2016.  
62. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness -implementation hybrid designs: 
combining elements of clinical effectiveness and implementation research to enhance public health 
impact. Medical Care 2012;50:217 -26. 
63. NIH Health Care Systems Research Collaboratory. Pragmatic Trials eBook. In rethinking Clinical Trials: A 
Living Texbook of Pragmatic Clinical Trials.  
64. Donner A, Klar N. Pi[INVESTIGATOR_551852]. American Journal of Pu blic 
Health 2004;94:[ADDRESS_863555] AH, Glenn BA, Glasgow RE, Balasubramanian BA, Chambers DA, Fernandez ME, Heurtin -Roberts S, 
Kessler R, Ory MG, Phillips SM, Ritzwoller DP, Roby [INVESTIGATOR_34484], Rodriguez HP, Sabo RT, Sheinfeld Gorin SN, Stange 
KC, Group MS. Design ing a valid randomized pragmatic primary care implementation trial: the my own 
health report (MOHR) project. Implement Sci 2013;8:73.  
66. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS -2 tool: designing trials 
that are fit for purpose. BMJ 2015;350:h2147.  
67. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, 
Magid DJ, Chalkidou K. A pragmatic -explanatory continuum indicator summary (PRECIS): a tool to help 
trial designers. Jou rnal of Clinical Epi[INVESTIGATOR_623] 2009;62:464 -75. 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.0 7 Apr 2017   58 68. Lynn J, Schuster JL, Kabcenell A. Improving care for the end of life: A sourncebook for health care 
managers and clinicians. [LOCATION_001], NY: Oxford University Press, 2000.  
69. Moss AH, Ganjoo J, Sharma S, Gan sor J, Senft S, Weaner B, Dalton C, MacKay K, Pellegrino B, 
Anantharaman P, Schmidt R. Utility of the "surprise" question to identify dialysis patients with high 
mortality. Clin J Am Soc Nephrol 2008;3:1379 -84. 
70. Cohen LM, Ruthazer R, Moss AH, Germain MJ . Predicting six -month mortality for patients who are on 
maintenance hemodialysis. Clin J Am Soc Nephrol 2010;5:72 -9. 
71. Carr D, Khodyakov D. Health care proxies: whom do young old adults choose and why? Journal of Health 
and Social Behavior 2007;48:[ADDRESS_863556] Scale for measuring the quality of end -of-
life decision making. Patient Education and Counseling 2006;61:[ADDRESS_863557] rategy and brochure for relatives of patients dying in the ICU. New England Journal of 
Medicine 2007;356:469 -78. 
74. Zigmond AS, Snaith RP. The hospi[INVESTIGATOR_56105]. Acta Psychiatrica Scandinavica 
1983;67:361 -70. 
75. Lowe B, Spi[INVESTIGATOR_4280], Gr afe K, Kroenke K, Quenter A, Zipfel S, Buchholz C, Witte S, Herzog W. Comparative 
validity of three screening questionnaires for DSM -IV depressive disorders and physicians' diagnoses. 
Journal of Affective Disorders 2004;78:[ADDRESS_863558] -traumatic stress: a psychometric evaluation of symptom --
and copi[INVESTIGATOR_645134] a Norwegian sample. Scandinavian Journal of Psychology 
1999;40:101 -8. 
77. Weisaeth L. Torture of a Norwegian ship's crew. Stress reactions, c opi[INVESTIGATOR_007], and psychiatric aftereffects. In: 
Wilson JP, Raphael B, editors. International Handbook of Traumatic Stress Syndromes. London: Plenum 
Press, 1993.  
78. Schelling G, Stoll C, Haller M, Briegel J, Manert W, Hummel T, Lenhart A, Heyduck M, Polasek J, Me ier M, 
Preuss U, Bullinger M, Schuffel W, Peter K. Health -related quality of life and posttraumatic stress disorder 
in survivors of the acute respi[INVESTIGATOR_1505]. Crit Care Med 1998;26:[ADDRESS_863559] -traumatic stress 
disorder (PTSD) in physically injured victims of non -domestic violence. A longitudinal study. Soc Psychiatry 
Psychiatr Epi[INVESTIGATOR_5541] 2007;42:583 -93. 
80. McLean KA. Healthcare provider acceptability of a behavior al intervention to promote adherence. 
Department of Psychology: University of Miami, 2013:434.  
81. Glasgow RE, McKay HG, Pi[INVESTIGATOR_74182], Reynolds KD. The RE -AIM framework for evaluating interventions: what 
can it tell us about approaches to chronic illness mana gement? Patient Education and Counseling 
2001;44:119 -27. 
SPI[INVESTIGATOR_644922] v13 
Protocol  4.8.2021  
NIH Clinical Trial Protocol Template – v1.[ADDRESS_863560] A, Castro F, Charns M. The sustainability of new programs 
and innovations: a review of the empi[INVESTIGATOR_311435]. 
Implement Sci 2012;7:17.  
83. Barnato AE, Farrell MH, Chang CC, Lave JR, Roberts MS, Angus DC. Development and validation of hospi[INVESTIGATOR_307] 
"end -of-life" treatment intensity measures. Medical Care 2009;47:1098 -105.  
84. Stange KC, Glasgow RE. Cons idering and Reporting Important Contextual Factors in Research on the 
Patient -Centered Medical Home. In: Quality AfHRa, editor. Rockville, MD: Agency for Healthcare Research 
and Quality, 2013.  
85. [LOCATION_002] Department of Agriculture. Urban influence co de. 2013.  
86. Gessert CE, Haller IV, Johnson BP. Regional variation in care at the end of life: discontinuation of dialysis. 
BMC Geriatr 2013;13:39.  
87. Watanabe -Galloway S, Zhang W, Watkins K, Islam KM, Nayar P, Boilesen E, Lander L, Wang H, Qiu F. 
Qualit y of end -of-life care among rural Medicare beneficiaries with colorectal cancer. Journal of Rural 
Health 2014;30:397 -405.  
88. Lavergne MR, Lethbridge L, Johnston G, Henderson D, D'Intino AF, McIntyre P. Examining palliative care 
program use and place of de ath in rural and urban contexts: a Canadian population -based study using 
linked data. Rural Remote Health 2015;15:3134.  
89. Wang H, Qiu F, Boilesen E, Nayar P, Lander L, Watkins K, Watanabe -Galloway S. Rural -Urban Differences in 
Costs of End -of-Life Care f or Elderly Cancer Patients in the [LOCATION_002]. Journal of Rural Health 2015.  
90. Verbeke G, Molenberghs G. Linear mized models for longitudinal data. [LOCATION_001]: Springer, 2009.  
91. Molenberghs G, Verbeke G. Models for discrete longitudinal data. [LOCATION_001]:  Springer, 2005.  
92. Ritzwoller DP, Sukhanova A, Gaglio B, Glasgow RE. Costing behavioral interventions: a practical guide to 
enhance translation. Annals of Behavioral Medicine 2009;37:218 -27. 
93. Hsieh HF, Shannon SE. Three approaches to qualitative conte nt analysis. Qualitative Health Research 
2005;15:[ADDRESS_863561]. Content analysis: review of methods and their applications in 
nutrition education. J Nutr Educ Behav 2002;34:224 -30. 
95. Miles MB, Huberman AM. Qualitative  Data Analysis:  An expanded sourcebook. 2nd ed ed. Thousand 
Oaks, CA: Sage Publishing, 1994.  
96. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology 2006;3:77 -
101.  
 
 